This work was partially supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology; the Japanese Ministry of Health, Labor, and Welfare; the Uehara Memorial Foundation; the Nagao Takeshi Nanbyo Foundation; the Kanagawa Nanbyo Foundation; the Mishima Kaiun Memorial Foundation; the Takeda Science Foundation; the ITSUU Laboratory Research Foundation; the

Abdelbary, N.H., Abdullah, H.M., Matsuzaki, T., Hayashi, D., Tanaka, Y., Takashima, H.,

Anderson, P., Nagler-Anderson, C., O'Brien, C., Levine, H., Watkins, S., Slayter, H.S., Blue,

Arnulf, B., Thorel, M., Poirot, Y., Tamouza, R., Boulanger, E., Jaccard, A., Oksenhendler, E.,

Asquith, B., Mosley, A.J., Barfield, A., Marshall, S.E., Heaps, A., Goon, P., Hanon, E., Tanaka,

Izumo, S. & Kubota, R. 2011. Reduced Tim-3 expression on human T-lymphotropic virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes in HTLV-I infection.

M.L. & Schlossman, S.F. 1990. A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T

Hermine, O. & Pique, C. 2004. Loss of the ex vivo but not the reinducible CD8+ Tcell response to Tax in human T-cell leukemia virus type 1-infected patients with

Y., Taylor, G.P. & Bangham, C.R. 2005. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in

Foundation for Total Health Promotion; and the Sankyo Foundation of Life Science.

*Journal of Infectious Diseases*, 203, 7, 948-959

lymphocytes. *Journal of Immunology*, 144, 2, 574–582

adult T-cell leukemia/lymphoma. *Leukemia*, 18, 1, 126-132

cells and virus-infected cells by producing perforins, granzymes, and IFN-γ. Human NK cells can be divided into 2 subsets on the basis of their cell-surface markers: CD56+CD16+ and CD56brightCD16– NK cells. CD56+CD16+ NK cells are the major population of NK cells and have natural cytotoxic activity. CD56brightCD16– NK cells are not cytotoxic but have the capacity to produce large amounts of IFN-γ upon activation. The activity of NK cells is regulated by a balance between positive and negative signals from different activating and inhibitory NK receptors. CD94/NKG2 receptor family is expressed on CD8+ T cells and T cells as well as NK cells, and is involved in the pathogenesis of HAM/TSP by modulating the activities of those cell populations (Saito et al. 2003, Mosley et al. 2005).

In both HIV-1- and HTLV-1-infected individuals, the number and function of NK cell subsets are impaired (Fortis et al., 2005). Multiple investigators have reported that the numbers of CD56+CD16+ NK cells in HAM/TSP and ATL patients are significantly lower than those observed in healthy controls (Azakami et al., 2009; Yu et al., 1991). Furthermore, NK cell activity was also lower in HAM/TSP patients than in healthy controls (Yu et al., 1991). When primary CD4+ T cells are infected by HTLV-1, they can escape from NK cellmediated cytotoxicity; HTLV-1 p12I downregulates the expression of intercellular adhesion molecule-1 (ICAM-1) and -2 on the surface of infected CD4+ T cells, resulting in a reduced adherence of NK cells to HTLV-1-infected CD4+ T cells (Banerjee et al., 2007).

#### **4.3 Natural killer T cells and HTLV-1**

Natural killer T (NKT) cells, a unique T cell subpopulation, constitute a subset of lymphocytes that share the features of innate and adaptive immune cells. Unlike conventional T cells, NKT cells express a TCR that recognizes glycolipids instead of protein antigens. Moreover, these cells share properties and receptors with NK cells. They rapidly produce granzymes and perforins upon stimulation. Among the CD3+ T cells in human blood, 10–25% express NK cell surface molecules such as CD161, and these cells are classified as NKT cells. A small population of T cells within this NKT cell subset expresses a highly conserved Vα24Jα18 TCR chain that preferentially associates with Vβ11; these T cells are referred to as iNKT cells. Activation of human iNKT cells requires the presentation of glycolipids such as α-galactosylceramide (α-GalCer) on the MHC class I-like molecule CD1d. α-GalCer induces the rapid production of cytokines and potent antitumor and antipathogen responses by iNKT cells. CD4– iNKT cells preferentially induce the Th1 response and are more important than CD4+ iNKT cells in controlling viral infection and cancer (Kim et al., 2002).

HIV-1-infected subjects have fewer iNKT cells in their peripheral blood than healthy donors (Sandberg et al., 2002; van der Vliet et al., 2002). The proliferative potential and INF-γ production of residual iNKT cells are impaired in HIV-1-infected individuals (Moll et al., 2009); likewise, patients with HTLV-1-associated disorders have a decreased frequency of iNKT cells in their peripheral blood (Azakami et al., 2009). Interestingly, in contrast to patterns observed in HIV-1 infections, HTLV-1 infection leads to preferential decreases of CD4– iNKT cells (Azakami et al., 2009). The production of perforin in iNKT cells is impaired in both ACs and HAM/TSP patients (Azakami et al., 2009). In addition, there is an inverse correlation between the frequency of iNKT cells and the HTLV-1 proviral load in the peripheral blood of HTLV-1-infected individuals (Azakami et al., 2009). Notably, *in vitro* stimulation of peripheral blood cells with α-GalCer leads to an increase in the number of iNKT cells and a subsequent decrease in the number of HTLV-1-infected T cells in samples from ACs (Azakami et al., 2009). These results suggest that iNKT cells contribute to the immune defense against HTLV-1, and that iNKT cell depletion plays an important role in the pathogenesis of HAM/TSP and ATL.

### **5. Conclusion**

72 T-Cell Leukemia

cells and virus-infected cells by producing perforins, granzymes, and IFN-γ. Human NK cells can be divided into 2 subsets on the basis of their cell-surface markers: CD56+CD16+ and CD56brightCD16– NK cells. CD56+CD16+ NK cells are the major population of NK cells and have natural cytotoxic activity. CD56brightCD16– NK cells are not cytotoxic but have the capacity to produce large amounts of IFN-γ upon activation. The activity of NK cells is regulated by a balance between positive and negative signals from different activating and inhibitory NK receptors. CD94/NKG2 receptor family is expressed on CD8+ T cells and T cells as well as NK cells, and is involved in the pathogenesis of HAM/TSP by modulating

In both HIV-1- and HTLV-1-infected individuals, the number and function of NK cell subsets are impaired (Fortis et al., 2005). Multiple investigators have reported that the numbers of CD56+CD16+ NK cells in HAM/TSP and ATL patients are significantly lower than those observed in healthy controls (Azakami et al., 2009; Yu et al., 1991). Furthermore, NK cell activity was also lower in HAM/TSP patients than in healthy controls (Yu et al., 1991). When primary CD4+ T cells are infected by HTLV-1, they can escape from NK cellmediated cytotoxicity; HTLV-1 p12I downregulates the expression of intercellular adhesion molecule-1 (ICAM-1) and -2 on the surface of infected CD4+ T cells, resulting in a reduced

Natural killer T (NKT) cells, a unique T cell subpopulation, constitute a subset of lymphocytes that share the features of innate and adaptive immune cells. Unlike conventional T cells, NKT cells express a TCR that recognizes glycolipids instead of protein antigens. Moreover, these cells share properties and receptors with NK cells. They rapidly produce granzymes and perforins upon stimulation. Among the CD3+ T cells in human blood, 10–25% express NK cell surface molecules such as CD161, and these cells are classified as NKT cells. A small population of T cells within this NKT cell subset expresses a highly conserved Vα24Jα18 TCR chain that preferentially associates with Vβ11; these T cells are referred to as iNKT cells. Activation of human iNKT cells requires the presentation of glycolipids such as α-galactosylceramide (α-GalCer) on the MHC class I-like molecule CD1d. α-GalCer induces the rapid production of cytokines and potent antitumor and antipathogen responses by iNKT cells. CD4– iNKT cells preferentially induce the Th1 response and are more important than CD4+ iNKT cells in controlling viral infection and

HIV-1-infected subjects have fewer iNKT cells in their peripheral blood than healthy donors (Sandberg et al., 2002; van der Vliet et al., 2002). The proliferative potential and INF-γ production of residual iNKT cells are impaired in HIV-1-infected individuals (Moll et al., 2009); likewise, patients with HTLV-1-associated disorders have a decreased frequency of iNKT cells in their peripheral blood (Azakami et al., 2009). Interestingly, in contrast to patterns observed in HIV-1 infections, HTLV-1 infection leads to preferential decreases of CD4– iNKT cells (Azakami et al., 2009). The production of perforin in iNKT cells is impaired in both ACs and HAM/TSP patients (Azakami et al., 2009). In addition, there is an inverse correlation between the frequency of iNKT cells and the HTLV-1 proviral load in the peripheral blood of HTLV-1-infected individuals (Azakami et al., 2009). Notably, *in vitro* stimulation of peripheral blood cells with α-GalCer leads to an increase in the number of iNKT cells and a subsequent decrease in the number of HTLV-1-infected T cells in samples

the activities of those cell populations (Saito et al. 2003, Mosley et al. 2005).

adherence of NK cells to HTLV-1-infected CD4+ T cells (Banerjee et al., 2007).

**4.3 Natural killer T cells and HTLV-1**

cancer (Kim et al., 2002).

Advances in our understanding of the immune system enhance studies of virus-host relationships. Although HTLV-1 causes 2 different diseases (ATL and HTM/TSP), CD4+CD25+CCR4+ T cells are the common viral reservoir in both disorders. According to recent studies, however, characteristics of CD4+CD25+CCR4+ T cells are completely different in the 2 diseases: Foxp3+ leukemic cells are found in ATL patients, while Foxp3- IFN- producing cells are found in HAM/TSP patients. The host immune system plays a crucial role in controlling these HTLV-1-infected cells. HTLV-1-specific CTL is activated in patients with HAM/TSP, but not in those with ATL, indicating that impairment of acquired immunity is not universal. However, both ATL and HAM/TSP patients are known to experience decreases in innate immunity via the functional impairment of DCs, NK cells, and iNKT cells, as well as lower overall population numbers of these cell types. These conditions may contribute to inadequate viral control and play an important role in the pathogenesis of HTLV-1-associated disorders.

#### **6. Acknowledgments**

This work was partially supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology; the Japanese Ministry of Health, Labor, and Welfare; the Uehara Memorial Foundation; the Nagao Takeshi Nanbyo Foundation; the Kanagawa Nanbyo Foundation; the Mishima Kaiun Memorial Foundation; the Takeda Science Foundation; the ITSUU Laboratory Research Foundation; the Foundation for Total Health Promotion; and the Sankyo Foundation of Life Science.

#### **7. References**

Host Immune System Abnormalities

1735–1743

72

Among Patients with Human T-Lymphotropic Virus Type 1 (HTLV-1)- Associated Disorders 75

Gessain, A., Barin, F. & Vernant, J.C. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. *Lancet*, 2, 8452, 407–410 Goon, P.K., Igakura, T., Hanon, E., Mosley, A.J., Barfield, A., Barnard, A.L., Kaftantzi, L.,

Grant, C., Oh, U., Yao, K., Yamano, Y. & Jacobson, S. 2008. Dysregulation of TGF-beta

Greten, T.F., Slansky, J.E., Kubota, R., Soldan, S.S., Jaffee, E.M., Leist, T.P., Pardoll, D.M.,

Harashima, N., Kurihara, K., Utsunomiya, A. Tanosaki, R., Hanabuchi, S., Masuda, M.,

Hayashi, D., Kubota, R., Takenouchi, N., Tanaka, Y., Hirano, R., Takashima, H., Osame, M.,

Hieshima, K., Nagakubo, D., Nakayama, T., Shirakawa, A.K., Jin, Z., & Yoshie, O. 2008. Tax-

Hilburn, S., Rowan, A., Demontis, M.A., MacNamara, A., Asquith, B., Bangham, C.R. &

Hori, S., Nomura, T. & Sakaguchi, S. 2003. Control of regulatory T cell development by the

Iwanaga, M., Watanabe, T., Utsunomiya, A., Okayama, A., Uchimaru, K., Koh, K.R., Ogata,

transcription factor Foxp3. *Science*, 299, 5609, 1057–1061

CCR4-expressing CD4+ T cells. *Journal of Immunol*ogy, 180, 2, 931-9

hematopoietic stem cell transplantation. *Cancer Research*, 64, 391–399 Hashimoto, K., Higuchi, I., Osame, M. & Izumo, S. 1998. Quantitative in situ PCR assay of

neuroinflammatory disease. *Blood*,111, 12, 5601–5609

National Academy of Sciences U.S.A., 95, 13, 7568–7573

*Neuroimmunology*, 200, 1-2, 115–124

*Haematology*, 125, 5, 568-575

Tanaka, Y., Taylor, G.P. Weber, J.N. & Bangham, C.R. 2004. Human T cell lymphotropic virus type I (HTLV-I)-specific CD4+ T cells: immunodominance hierarchy and preferential infection with HTLV-I. *Journal of Immunology*, 172, 3,

signaling and regulatory and effector T-cell function in virus-induced

Jacobson, S. & Schneck, J.P. 1998. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proceedings of the

Ohashi, T., Fukui, F., Hasegawa, A., Masuda, T., Takaue, Y., Okamura, J. & Kannagi, M. 2004. Graft-versus-Tax response in adult T-cell leukemia patients after

HTLV-1 infected cells in peripheral blood lymphocytes of patients with ATL, HAM/TSP and asymptomatic carriers. *Journal of the Neurological Sciences*, 159, 1, 67–

Izumo, S. & Arimura, K. 2008. Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-I-associated myelopathy. *Journal of*

inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to

Taylor, G.P. 2011. In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome. *Journal of Infectious Diseases*, 203, 4, 529-36 Hishizawa M, Imada K, Kitawaki T, Ueda M, Kadowaki N, Uchiyama T. 2004. Depletion

and impaired interferon-alpha-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. *British Journal of*

M., Kikuchi, H., Sagara, Y., Uozumi, K., Mochizuki, M., Tsukasaki, K., Saburi, Y., Yamamura, M., Tanaka, J., Moriuchi, Y., Hino, S., Kamihira, S. & Yamaguchi, K. 2010.  *Journal of General Virology*, 86, 5, 1515–23

Azakami, K., Sato, T., Araya, N., Utsunomiya, A., Kubota, R., Suzuki, K., Hasegawa, D.,

Banerjee, P., Feuer, G., Barker, E. 2007. Human T-cell leukemia virus type 1 (HTLV-1) p12I

Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M. & Koup,

Biddison, W.E., Kubota, R., Kawanishi, T., Taub, D.D., Cruikshank, W.W., Center, D.M.,

Bieganowska, K., Hollsberg, P., Buckle, G.J., Lim, D.G., Greten, T.F., Schneck, J., Altman,

Chen, S., Ishii, N., Ine, S., Ikeda, S., Fujimura, T., Ndhlovu, L.C., Soroosh, P., Tada, K.,

Elovaara, I., Koenig, S., Brewah, A.Y., Woods, R.M., Lehky, T. & Jacobson, S. 1993. High

Enose-Akahata, Y., Oh, U., Grant, C. & Jacobson, S. 2008. Retrovirally induced CTL

Fortis, C. & Poli, G. 2005. Dendritic cells and natural killer cells in the pathogenesis of HIV

virus-associated myelopathy. *Journal of Immunology*, 162, 3, 1765–1771. Boxus, M. & Willems, L. 2009. Mechanisms of HTLV-1 persistence and transformation.

metalloproteinase. *Journal of Immunology*, 159, 4, 2018–2025

Bangham, C.R. 2008. HTLV-1 infection: role of CTL efficiency. *Blood*, 112, 6, 2176-2177 Bangham, C.R. 2009. CTL quality and the control of human retroviral infections. *European*

1515–23

65–78

2, 269–277

2400–2410

disorders. *Blood*, 114, 15, 3208-3215

*Journal of Immunology*, 39, 7, 1700-1712

*British Journal of Cancer*, 101, 9, 1497-1501

*Journal of Experimental Medicine*, 177, 6, 1567–1573

infection. *Immunologic Research*, 33: 1, 1-21

human T-lymphotropic virus type 1 proviral load. *Journal of General Virology*, 86, 5,

Izumi, T., Fujita, H., Aratani, S., Fujii, R., Yagishita, N., Kamijuku, H., Kanekura, T., Seino, K., Nishioka, K., Nakajima, T. & Yamano, Y. 2009. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated

down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells. *Journal of Virology*, 81, 18 9707-9717

R.A. 2003. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. *Journal of Immunological Methods*, 281, 1-2,

Connor, E.W., Utz, U. & Jacobson, S. 1997. Human T cell leukemia virus type I (HTLV-I)-specific CD8+ CTL clones from patients with HTLV-I-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix

J.D., Jacobson, S., Ledis, S.L., Hanchard, B., Chin, J., Morgan, O., Roth, P.A. & Hafler, D.A. 1999. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic

Harigae, H., Kameoka, J., Noriyuki, K., Sasaki, T. & Sugamura, K. 2006. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. *International Immunology* 18,

human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease.

degranulation mediated by IL-15 expression and infection of mononuclear phagocytes in patients with HTLV-Iassociated neurologic disease. *Blood*, 112, 6,

Host Immune System Abnormalities

1699-1706

*Hematology,* 84, 1, 63–69

*of Neuroimmune Pharmacology*, 5, 3, 310-25

paraparesis. *BMC Immunology,* 9, 41

*Neurovirology*, 4, 6, 586-593

812

*Journal of Infectious Diseases*, 183, 2, 197–205

Journal of Neurovirology, 8, 1, 53–57

Among Patients with Human T-Lymphotropic Virus Type 1 (HTLV-1)- Associated Disorders 77

Kubota, R., Soldan, S.S., Martin, R. & Jacobson, S. 2002. Selected cytotoxic T lymphocytes

Levin, M.C., Lehky, T.J., Flerlage, A.N., Katz, D., Kingma, D.W., Jaffe, E.S., Heiss, J.D.,

Macnamara, A., Rowan, A., Hilburn, S., Kadolsky, U., Fujiwara, H., Suemori, K., Yasukawa,

Matsuura, E., Yamano, Y. & Jacobson, S. 2010. Neuroimmunity of HTLV-I Infection. *Journal*

Michaëlsson, J., Barbosa, H.M., Jordan, K.A., Chapman, J.M., Brunialti, M.K., Neto, W.K.,

Moll, M., Kuylenstierna, C., Gonzalez, V.D., Andersson, S.K., Bosnjak, L., Sönnerborg, A.,

Mosley, A.J., Asquith, B. & Bangham, C.R. 2005. Cell-mediated immune response to human

Nagai, M., Usuku, K., Matsumoto, W., Kodama, D., Takenouchi, N., Moritoyo, T.,

Nagai, M., Kubota, R., Greten, T.F., Schneck, J.P., Leist, T.P. & Jacobson, S. 2001a. Increased

Nagai, M., Yamano, Y., Brennan, M.B., Mora, C.A. & Jacobson, S. 2001b. Increased HTLV-I

infection. *European Journal of Immunology*, 39, 3, 902-911

T-lymphotropic virus type I. *Viral Immunology*, 18, 2, 293-305

determines outcome in HTLV-1 infection. *PLoS Pathogens*, 6, 9, e1001117 Matsubar, Y., Hori, T., Morita, R., Sakaguchi, S. & Uchiyama, T. 2006. Delineation of

with high specificity for HTLV-I in cerebrospinal fluid from a HAM/TSP patient.

Patronas, N., McFarland, H.F. & Jacobson, S. 1997. Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus type Iassociated neurologic disease. *New England Journal of Medicine*, 336, 12, 839–845 Macatonia, S.E., Cruickshank, J.K., Rudge, P. & Knight, S.C. 1992. Dendritic cells from

patients with tropical spastic paraparesis are infected with HTLV-1 and stimulate autologous lymphocyte proliferation. *AIDS Research and Human Retroviruses*, 8, 9,

M., Taylor, G., Bangham, C.R. & Asquith, B. 2010. HLA class I binding of HBZ

immunoregulatory properties of adult T-cell leukemia cells. *International Journal of*

Nukui, Y., Sabino, E.C., Chieia, M.A., Oliveira, A.S.B., Nixon, D.F. & Kallas, E.G. 2008. The frequency of CD127low expressing CD4+CD25high T regulatory cells is inversely correlated with human T lymphotrophic virus type-1 (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated myelopathy/tropical spastic

Quigley, M.F. & Sandberg, J.K. 2009.Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1

Hashiguchi, S., Ichinose, M., Bangham, C.R., Izumo, S. & Osame, M. 1998. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. *Journal of*

activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load.

proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. *Annals of Neurology*, 50, 6, 807–

progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. *Blood*, 116, 8, 1211-1219

Jacobson, S., Shida, H., McFarlin, D.E., Fauci, A.S. & Koenig, S. 1990. Circulating CD8+

Jacobson, S. 2002. Immunopathogenesis of human T cell lymphotropic virus type Iassociated neurologic disease. *Journal of Infectious Diseases*, 186 Suppl, S187–92 Jones, K.S., Petrow-Sadowski, C., Huang, Y.K., Bertolette, D.C. & Ruscetti, F.W. 2008. Cell-

Kannagi, M., Sugamura, K., Kinoshita, K., Uchino, H. & Hinuma, Y. 1984. Specific cytolysis

Kannagi, M. Immunologic control of human T-cell leukemia virus type I and adult T-cell

Kannagi, M., Hasegawa, A., Kinpara, S., Shimizu, Y., Takamori, A. & Utsunomiya, A. 2011.

Karube, K., Ohshima, K., Tsuchiya, T., Yamaguchi, T., Kawano, R., Suzumiya, J.,

Kim, C.H., Butcher, E.C. & Johnston, B. 2002. Distinct subsets of human Valpha24-invariant

Kohno, T., Yamada, Y., Akamatsu, N., Kamihira, S., Imaizumi, Y., Tomonaga, M. &

Kozako, T., Arima, N., Toji, S., Masamoto, I., Akimoto, M., Hamada, H., Che, X.F., Fujiwara,

Kubota, R., Fujiyoshi, T., Izumo, S., Yashiki, S., Maruyama, I., Osame, M. & Sonoda, S. 1993.

HTLV-I-associated myelopathy. *Journal of Neuroimmunology*, 42, 2, 147–154 Kubota, R., Nagai, M., Kawanishi, T., Osame, M. & Jacobson, S. 2000. Increased HTLV type 1

leukemia. 2007. International Journal of Hematology, 86, 2, 113–117

leukemia/lymphoma patient. *Journal of Immunology,* 133, 2, 1037-1041. Kannagi, M., Harada, S., Maruyama, I. Inoko, H., Igarashi, H., Kuwashima, G., Sato, S.,

Japan. *Blood*, 116, 8, 1211-1219

neurological disease. *Nature*, 348, 6298, 245–248

CD4(+) T cells. *Nature Medicine*, 14, 4, 429-436

cells. *International Immunology,* 3, 8, 761–7

acquired immunity. *Cancer Science*, 102, 4, 670-6

cells. *British Journal of Haematology,* 126, 1, 81–84

*Immunology*, 23, 11, 516-519

*of Immunology*, 177, 8, 5718–5726

*Retroviruses*, 16, 16, 1705–1709

8, 527–533

progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in

cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated

free HTLV-1 infects dendritic cells leading to transmission and transformation of

of fresh tumor cells by an autologous killer T cell line derived from an adult T cell

Morita, M., Kidokoro, M., Sugimoto, M., Funahashi, S., Osame, M. & Shida, H. 1991. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV- I-infected

Double control systems for human T-cell leukemia virus type 1 by innate and

Utsunomiya, A., Harada, M. & Kikuchi, M. 2004. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma

NKT cells: cytokine responses and chemokine receptor expression. *Trends in*

Matsuyama, T. 2005. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. *Cancer Science, 96*,

H., Matsushita, K., Tokunaga, M., Haraguchi, K., Uozumi, K., Suzuki, S., Takezaki, T. & Sonoda, S. 2006. Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. *Journal*

Fluctuation of HTLV-I proviral DNA in peripheral blood mononuclear cells of

tax specific CD8+ cells in HTLV type 1-associated myelopathy/tropical spastic paraparesis: correlation with HTLV type 1 proviral load. *AIDS Research and Human*

Host Immune System Abnormalities

Among Patients with Human T-Lymphotropic Virus Type 1 (HTLV-1)- Associated Disorders 79

Satou, Y & Matsuoka, M. 2010. HTLV-1 and the host immune system: how the virus

Satou, Y., Yasunaga, J., Zhao, T., Yoshida, M., Miyazato, P., Takai, K., Shimizu, K., Ohshima,

Shimauchi, T., Kabashima, K. & Tokura, Y. 2008. Adult T-cell leukemia/lymphoma cells

Shimizu, Y., Takamori, A., Utsunomiya, A., Kurimura, M., Yamano, Y., Hishizawa, M.,

Toulza, F., Heaps, A., Tanaka, Y., Taylor, G.P. & Bangham, C.R. 2008. High frequency of

Tsuji, M., Komatsu, N., Kawamoto, S., Suzuki, K., Kanagawa, O., Honjo, T., Hori, S. &

Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K. & Uchino, H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. 1977. *Blood*, 50, 3, 481-92 Umehara, F., Izumo, S., Nakagawa, M., Ronquillo, A.T., Takahashi, K., Matsumuro, K., Sato,

Umehara, F., Nakamura, A., Izumo, S., Kubota, R., Ijichi, S., Kashio, N., Hashimoto, K.,

van der Vliet, H.J., von Blomberg, B.M., Hazenberg, M.D., Nishi, N., Otto, S.A., van

Wodarz, D., Nowak, M.A. & Bangham, C.R. 1999. The dynamics of HTLV-I and the CTL

Wodarz, D., Hall, S.E., Usuku, K., Osame, M., Ogg, G.S., McMichael, A.J., Nowak, M.A. &

*Clinical and Experimental Hematopathology*. 50, 1, 1-8

smoldering stages. *Cancer Science,* 100, 3, 481–489

T cells in gut Peyer's patches. *Science* 323, 5920, 1488–1492

CTL response. *Blood* 111, 10, 5047–5053

*Experimental Neurology*, 52, 4, 424–430

*Experimental Neurology*, 53, 6, 617–624

response. *Immunology Today,* 20, 5, 220–227

168, 3, 1490-1495

vivo. *PLoS Pathogens,* 7, 2, e1001274

*Science,* 99, 1, 98–106

disrupts immune regulation, leading to HTLV-1 associated diseases. *Journal of*

K., Green, P.L., Ohkura, N., Yamaguchi, T., Ono, M., Sakaguchi, S. & Matsuoka, M. 2011. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in

from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. *Cancer*

Hasegawa, A., Kondo, F., Kurihara, K., Harashima, N., Watanabe, T., Okamura, J., Masuda, T. & Kannagi, M. 2009. Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and

CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific

Fagarasan, S. 2009. Preferential generation of follicular B helper T cells from Foxp3+

E. & Osame M. 1993. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-Iassociated myelopathy. *Journal of Neuropathology and*

Usuku, K., Sato, E. & Osame, M. 1994. Apoptosis of T lymphocytes in the spinal cord lesions in HTLV-I-associated myelopathy: a possible mechanism to control viral infection in the central nervous system. *Journal of Neuropathology and*

Benthem, B.H., Prins, M., Claessen, F.A., van den Eertwegh, A.J., Giaccone, G., Miedema, F., Scheper, R.J. & Pinedo, H.M. 2002. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. *Journal of Immunology*,

Bangham, C.R.M.. 2001.  Proceedings of the Royal Society of London B, 268, 1473, 1215–21Yamano, Y., Nagai, M., Brennan, M. Mora, C.A., Soldan, S.S., Tomaru, U., Takenouchi, N., Izumo, S., Osame, M. & Jacobson, S. 2002. Correlation of human T-cell

Oh, U., Grant, C., Griffith, C., Fugo, K., Takenouchi, N. & Jacobson, S. 2006. Reduced Foxp3

Ohsugi, T. & Kumasaka, 2011. T. Low CD4/CD8 T-cell ratio associated with inflammatory

Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M. & Tara, M.

Parker, C.E., Daenke, S., Nightingale, S. & Bangham, C.R. 1992. Activated, HTLV-1-specific

Pique, C., Ureta-Vidal, A., Gessain, A., Chancerel, B., Gout, O., Tamouza, R., Agis, F. &

against viral peptides. 2000. *Journal of Experimental Medicine*, 191, 3, 567–72 Ramirez, J.M., Brembilla, N.C., Sorg, O., Chicheportiche, R., Matthes, T., Dayer, J.M., Saurat,

Richardson, J.H., Edwards, A.J., Cruickshank, J.K., Rudge, P. & Dalgleish, A.G. In vivo

Roncador, G., Garcia, J.F., Maestre, L., Lucas, E., Menarguez, J., Ohshima, K., Nakamura, S.,

Sabouri, A.H., Usuku, K., Hayashi, D., Izumo, S., Ohara, Y., Osame, M. & Saito, M. 2008

T cells in HTLV-1-associated neurologic disease. *Blood,* 112, 6, 2411–2420 Saito, M., Braud, V.M., Goon, P., Hanon, E., Taylor, G.P., Saito, A., Eiraku, N., Tanaka, Y.,

Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. 1995. Immunologic self-

Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. 2008. Regulatory T cells and immune

Sandberg, J.K., Fast, N.M., Palacios, E.H., Fennelly, G., Dobroszycki, J., Palumbo, P., Wiznia,

Sato, T., Araya, N. & Yamano, Y. 2011. Human T-lymphotropic virus type 1 (HTLV-1) and

autoimmune diseases. *Journal of Immunology,* 155, 3, 1151–1164

innate immunity. *Inflammation and Regeneration*, 31, 1, 110-115

with tropical spastic paraparesis. *Virology*. 188, 2, 628-636

cells. *European Journal of Immunology,* 40, 9, 2450–2459

leukaemia/lymphoma. *Leukemia,* 19, 12, 2247–2253

6, 4, e18518

11, 5682–5687

102, 2, 577-584

tolerance. *Cell,* 133, 5, 775–787

infection. *Journal of Virology*, 76, 15, 7528-7534

1032

protein expression is associated with inflammatory disease during human t lymphotropic virus type 1 Infection. *Journal of Infectious Diseases*, 193, 11, 1557–1566

arthropathy in human T-cell leukemia virus type I Tax transgenic mice. *PLoS One*,

1986. HTLV-I associated myelopathy, a new clinical entity. *Lancet* 1, 8488, 1031–

cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients

Dokhélar, M.C. Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed

J.H., Roosnek, E., & Chizzolini, C. 2010. Activation of the aryl hydrocarbon receptor reveals distinct requirements for IL-22 and IL-17 production by human T helper

cellular tropism of human T-cell leukemia virus type 1. 1990. *Journal of Virology*, 64,

Banham, A.H., Piris, M.A. FOXP3, a selective marker for a subset of adult T-cell

Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+

Usuku, K., Weber, J.N., Osame, M. & Bangham, C.R. 2003. Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriers. *Blood*,

tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various

A., Grant, R.M., Bhardwaj, N., Rosenberg, M.G. & Nixon, D.F. 2002. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus

**5**

*Japan*

**Constitutive Activation of the JAK/STAT and**

Adult T-cell leukemia/lymphoma (ATLL) caused by the retrovirus human T-cell leukemia virus type 1 (HTLV-1) infection is one of aggressive mature CD4+ T-cell neoplasms with a marked expansion of leukemic cells during the acute phase. ATLL is endemic in several regions of the world, especially in southwest Japan, the Caribbean basin, and parts of Central Africa. ATLL is divided into four clinical subtypes: acute, chronic, smoldering, and lymphoma type, based on the number of leukemic cells in peripheral blood, serum lactic acid dehydrogenase level, tumor lesions in various organs, and clinical course. The acute and lymphoma types still have an extremely poor prognosis, despite the advance in chemotherapy. Chemotherapy for ATLL has limited efficacy with median survivals of

The HTLV-1 genome encodes not only structural proteins, but also non-structural proteins such as Tax, Rex, p13, p12, p30, p21Rex and HTLV-1 bZIP factor (HBZ). The functional analysis of the viral proteins such as Tax has shed light on the pathogenesis of ATLL. Tax is a crucial viral protein encoded by the pX region, which can induce viral replication and a variety of cellular genes associated with cytokine production, inhibition of apoptosis and cell cycle dysregulation (Arima 1999, Azimi 1998, Geleziunas 1998, Kanno 1994, Mori 1996b). Tax-induced gene regulation, which is linked to malignant transformation of HTLV-1-infected T-cells, has been shown to be mediated by CREB/ATF, NF-B and SRF pathways. Constitutive activation of NF-B is one of common features of HTLV-1–transformed T-cells and ATLL leukemic cells, since inhibition of NF-B activity reduces cell growth and induces apoptosis of cells, suggesting a central role of NF-B in their proliferation and survival. Moreover, Tax binds to the upstream kinase, the mitogen-activated protein kinase/ERK kinase kinase-1 and enhance its kinase activity (Harhaj 1999, Huang 2002, Jin 1999). Nevertheless, ATLL develops in a period 40 to 60 years after initial infection, indicating that the development of ATLL requires a multistep oncogenic process including accumulation of genetic mutations. HTLV-1 infection alone is not sufficient to induce neoplastic transformation of infected cells. In fact, viral gene expression is at extremely low levels in primary ATLL cells (Franchini 1984). Thus,

the mechanism which develops ATLL still remains unclear.

**1. Introduction**

approximate one year.

**Toll-Like Receptor Signaling Pathways in**

**Adult T-Cell Leukemia/Lymphoma**

Hiroaki Morimoto and Junichi Tsukada *Cancer Chemotherapy Center and Hematology*

Takehiro Higashi, Takefumi Katsuragi, Atsushi Iwashige,

*University of Occupational and Environmental Health, Kitakyushu*

lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virusspecific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAMTSP). *Blood* 99, 1, 88–94

### **Constitutive Activation of the JAK/STAT and Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma**

Takehiro Higashi, Takefumi Katsuragi, Atsushi Iwashige, Hiroaki Morimoto and Junichi Tsukada *Cancer Chemotherapy Center and Hematology University of Occupational and Environmental Health, Kitakyushu*

*Japan*

#### **1. Introduction**

80 T-Cell Leukemia

Yamano, Y., Takenouchi, N., Li, H.C., Tomaru, U., Yao, K., Grant, C.W., Maric, D.A. &

Yamano, Y., Araya, N., Sato, T., Utsunomiya, A., Azakami, K., Hasegawa, D., Izumi, T.,

Yu, F., Itoyama, Y., Fujihara, K. & Goto, I. 1991. Natural killer (NK) cells in HTLV-I-

Yoshie, O., Imai, T. & Nomiyama, H. 2001. Chemokines in immunity. *Advances in*

Yoshie, O., Fujisawa, R., Nakayama, T., Harasawa, H., Tago, H., Izawa, D., Hieshima, K.,

Zhu, J. & Paul, W.E. 2010. Heterogeneity and plasticity of T helper cells. Cell Research, 20, 1,

T-cell leukemia virus type 1-transformed T cells. *Blood,* 99, 5, 1505–11 Zhou, X., Bailey-Bucktrout, S.L., Jeker, L.T., Penaranda, C., Martinez-Llordella, M., Ashby,

*Blood* 99, 1, 88–94

8, e6517

4-12

*Investigations*, 115, 5, 1361–1368

Neuroimmunology, 33, 2, 121-128

vivo. *Nature Immunology,* 10, 9, 1000–1007

*Immunology,* 78, 57–110

lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virusspecific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAMTSP).

Jacobson, S. 2005. Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease. *Journal of Clinical*

Fujita, H., Aratani, S., Yagishita, N., Fujii, R., Nishioka, K., Jacobson, S. & Nakajima, T. 2009. Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. *PLoS One, 4*,

associated myelopathy/tropical spastic paraparesis-decrease in NK cell subset populations and activity in HTLV-I seropositive individuals. Journal of

Tatsumi, Y., Matsushima, K., Hasegawa, H., Kanamaru, A., Kamihira, S. & Yamada, Y. 2002. Frequent expression of CCR4 in adult T-cell leukemia and human

M., Nakayama, M., Rosenthal, W. & Bluestone, J.A. 2009. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in Adult T-cell leukemia/lymphoma (ATLL) caused by the retrovirus human T-cell leukemia virus type 1 (HTLV-1) infection is one of aggressive mature CD4+ T-cell neoplasms with a marked expansion of leukemic cells during the acute phase. ATLL is endemic in several regions of the world, especially in southwest Japan, the Caribbean basin, and parts of Central Africa. ATLL is divided into four clinical subtypes: acute, chronic, smoldering, and lymphoma type, based on the number of leukemic cells in peripheral blood, serum lactic acid dehydrogenase level, tumor lesions in various organs, and clinical course. The acute and lymphoma types still have an extremely poor prognosis, despite the advance in chemotherapy. Chemotherapy for ATLL has limited efficacy with median survivals of approximate one year.

The HTLV-1 genome encodes not only structural proteins, but also non-structural proteins such as Tax, Rex, p13, p12, p30, p21Rex and HTLV-1 bZIP factor (HBZ). The functional analysis of the viral proteins such as Tax has shed light on the pathogenesis of ATLL. Tax is a crucial viral protein encoded by the pX region, which can induce viral replication and a variety of cellular genes associated with cytokine production, inhibition of apoptosis and cell cycle dysregulation (Arima 1999, Azimi 1998, Geleziunas 1998, Kanno 1994, Mori 1996b). Tax-induced gene regulation, which is linked to malignant transformation of HTLV-1-infected T-cells, has been shown to be mediated by CREB/ATF, NF-B and SRF pathways. Constitutive activation of NF-B is one of common features of HTLV-1–transformed T-cells and ATLL leukemic cells, since inhibition of NF-B activity reduces cell growth and induces apoptosis of cells, suggesting a central role of NF-B in their proliferation and survival. Moreover, Tax binds to the upstream kinase, the mitogen-activated protein kinase/ERK kinase kinase-1 and enhance its kinase activity (Harhaj 1999, Huang 2002, Jin 1999). Nevertheless, ATLL develops in a period 40 to 60 years after initial infection, indicating that the development of ATLL requires a multistep oncogenic process including accumulation of genetic mutations. HTLV-1 infection alone is not sufficient to induce neoplastic transformation of infected cells. In fact, viral gene expression is at extremely low levels in primary ATLL cells (Franchini 1984). Thus, the mechanism which develops ATLL still remains unclear.

Constitutive Activation of the JAK/STAT

prognostic significance for STAT3 (Benekli 2002).

proliferation with constitutive JAK-STAT activity.

with poor response to therapy and overall prognosis.

And Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma 83

Recent reports have emphasized the significance of STATs in oncogenesis (Akira 1997) and leukemogenesis (Bowman 2000, Lin 2000, Levy 2000, Coffer 2000, Akira 1997). Many oncoproteins can activate STATs. In contrast to the normal cellular response, which shows rapid and transient activation of STATs, aberrant activation of JAK-STAT signaling contributes to malignant transformation. The v-abl oncogene of the Abelson murine leukemia virus (A-MuLV) induces JAK-STAT signaling, involving Jak1 and Jak3 (Danial 1995). Interestingly, constitutive expression of a dominant-active STAT3 induces neoplastic transformation (Bromberg 1999). STAT1 and STAT5 are active in BCR-ABL-positive leukemias (Carlesso 1996, Shuai 1996, Frank 1996) and STAT1, STAT3 and STAT5 are constitutively activated in acute leukemia blasts (Gouilleux-Gruart 1996, Weber-Nordt 1996, Xia 1998, Spiekermann 2001). A constitutively active form of STAT3 can transform cells (Bromberg 1999). Constitutive activation of Jaks and STATs has been observed in murine pre-B lymphocytes transformed with the A-MuLV(Danial 1995), human B cells transformed with Epstein-Barr virus (Gouilleux-Gruart 1996) and murine erythroleukemia induced by spleen focus-forming virus (Ohashi 1995). Primary acute leukemia cells also show constitutive activation of STATs (Gouilleux-Gruart 1996, Weber-Nordt 1996, Xia 1998, Spiekermann 2001). Moreover, constitutive STAT3 activation in acute myeloid leukemia blasts has been reported to be associated with short disease-free survival, showing a

HLTV-1 infects and immortalizes primary human T-cells. In early stage, the viral regulatory proteins Tax and Rex are involved in the up-regulation of IL-2 and IL-2R. In some ATL cases, IL-2 and IL-15 can induce growth of ATLL cells (Arima 1996, Maeda 1987, Yamada 1998) (Fig. 1). Phosphorylation of STAT3 and STAT5 in ATL cells is induced by IL-2, IL-15 and IL-21 (Ueda 2005). A paracrine growth loop that involves Tax-induced IL-9 production in ATL cells

However, constitutive activation of the JAK-STAT pathway is generally correlated with IL-2 independence. Transformation of T-cells by HTLV-1 is associated with constitutive activation of the JAK-STAT pathway (Migone 1995, Xu 1995) (Fig1). Migone *et al*. (Migone 1995) demonstrated activation of Jak1, Jak3, STAT3 and STAT5 correlated with the transition from an IL-2-dependent to an IL-2-independent phase in HTLV-1-transformed cells. Spontaneous phosphorylation of Jak2 and Jak3 has also been observed in T-cells transformed with HTLV-1 (Xu 1995). Leukemia cells obtained from ATL patients also showed constitutive activation of STATs (Takemoto 1997, Tsukada 2000). Takemoto *et al*.(Takemoto 1997) observed constitutive activation of STAT1, STAT3 and STAT5 in leukemic cells of ATL patients, and demonstrated the association of leukemic cell

In addition, no gain-of-function mutations of the Jak1 and Jak3 in primary ATLL cells has been detected (Kameda 2010). These data are contrast to the results obtained from acute Tlymphoblastic leukemia (T-ALL). Flex *et al*. demonstrated that *JAK1* gene mutations occur in ALL and are more frequently observed among adult individuals with involvement of the T cell lineage (Flex 2008). The mutations promote gain of kinase function, and are associated

**2.1 Unique function of the Jak-STAT signaling pathway in HTLV-1-infected T-cells**  HTLV-1 infection up-regulates expression of the suppressor of cytokine signaling 1 (SOCS1). HTLV-1-induced SOCS1 inhibits the type I IFN antiviral response against HTLV-1 by

and expression of IL-9 receptor on monocytes has been also observed (Chen 2008).

The general subject of signaling pathways in ATLL cells and HTLV-1-transformed cells has been covered by many excellent original reports and reviews. In this review, authors focus on recent advances of two signaling pathways in ATLL cells and HTLV-1–transformed Tcells; the JAK (Janus kinase)-STAT (signal transducer and activator of transcription) and TLR (Toll-like receptor) signaling pathways.

#### **2. Constitutive activation of the JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells**

STAT proteins play important roles in regulating cellular response to a variety of cytokines. STATs are latent cytosolic transcriptional factors that are activated by tyrosine phosphorylation in response to cytokines. The four mammalian members of the JAK family (Jak1, Jak2, Jak3, and Tyk2) are non-receptor tyrosine kinases functioning as signal transducers, that control activation of STATs. Jaks associate constitutively with cytokine receptors, and promote signals by phosphorylating tyrosine residues of activated receptors to allow the recruitment and activation of STAT proteins. STATs can form homo- or heterodimers in which amino acid sequence containing a phospho-tyrosine residue in one partner binds to the SH2 domain in the other vice versa, leading to nuclear translocation of STAT dimers and their participation in transcriptional regulation of various cytokine responsive genes (Darnell 1997, Ihle 2001, Leonard 1998).

Fig. 1. The JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells.

The general subject of signaling pathways in ATLL cells and HTLV-1-transformed cells has been covered by many excellent original reports and reviews. In this review, authors focus on recent advances of two signaling pathways in ATLL cells and HTLV-1–transformed Tcells; the JAK (Janus kinase)-STAT (signal transducer and activator of transcription) and

**2. Constitutive activation of the JAK-STAT signaling pathway in ATLL cells**

Fig. 1. The JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells.

STAT proteins play important roles in regulating cellular response to a variety of cytokines. STATs are latent cytosolic transcriptional factors that are activated by tyrosine phosphorylation in response to cytokines. The four mammalian members of the JAK family (Jak1, Jak2, Jak3, and Tyk2) are non-receptor tyrosine kinases functioning as signal transducers, that control activation of STATs. Jaks associate constitutively with cytokine receptors, and promote signals by phosphorylating tyrosine residues of activated receptors to allow the recruitment and activation of STAT proteins. STATs can form homo- or heterodimers in which amino acid sequence containing a phospho-tyrosine residue in one partner binds to the SH2 domain in the other vice versa, leading to nuclear translocation of STAT dimers and their participation in transcriptional regulation of various cytokine

TLR (Toll-like receptor) signaling pathways.

responsive genes (Darnell 1997, Ihle 2001, Leonard 1998).

**and HTLV-1-transformed T-cells**

Recent reports have emphasized the significance of STATs in oncogenesis (Akira 1997) and leukemogenesis (Bowman 2000, Lin 2000, Levy 2000, Coffer 2000, Akira 1997). Many oncoproteins can activate STATs. In contrast to the normal cellular response, which shows rapid and transient activation of STATs, aberrant activation of JAK-STAT signaling contributes to malignant transformation. The v-abl oncogene of the Abelson murine leukemia virus (A-MuLV) induces JAK-STAT signaling, involving Jak1 and Jak3 (Danial 1995). Interestingly, constitutive expression of a dominant-active STAT3 induces neoplastic transformation (Bromberg 1999). STAT1 and STAT5 are active in BCR-ABL-positive leukemias (Carlesso 1996, Shuai 1996, Frank 1996) and STAT1, STAT3 and STAT5 are constitutively activated in acute leukemia blasts (Gouilleux-Gruart 1996, Weber-Nordt 1996, Xia 1998, Spiekermann 2001). A constitutively active form of STAT3 can transform cells (Bromberg 1999). Constitutive activation of Jaks and STATs has been observed in murine pre-B lymphocytes transformed with the A-MuLV(Danial 1995), human B cells transformed with Epstein-Barr virus (Gouilleux-Gruart 1996) and murine erythroleukemia induced by spleen focus-forming virus (Ohashi 1995). Primary acute leukemia cells also show constitutive activation of STATs (Gouilleux-Gruart 1996, Weber-Nordt 1996, Xia 1998, Spiekermann 2001). Moreover, constitutive STAT3 activation in acute myeloid leukemia blasts has been reported to be associated with short disease-free survival, showing a prognostic significance for STAT3 (Benekli 2002).

HLTV-1 infects and immortalizes primary human T-cells. In early stage, the viral regulatory proteins Tax and Rex are involved in the up-regulation of IL-2 and IL-2R. In some ATL cases, IL-2 and IL-15 can induce growth of ATLL cells (Arima 1996, Maeda 1987, Yamada 1998) (Fig. 1). Phosphorylation of STAT3 and STAT5 in ATL cells is induced by IL-2, IL-15 and IL-21 (Ueda 2005). A paracrine growth loop that involves Tax-induced IL-9 production in ATL cells and expression of IL-9 receptor on monocytes has been also observed (Chen 2008).

However, constitutive activation of the JAK-STAT pathway is generally correlated with IL-2 independence. Transformation of T-cells by HTLV-1 is associated with constitutive activation of the JAK-STAT pathway (Migone 1995, Xu 1995) (Fig1). Migone *et al*. (Migone 1995) demonstrated activation of Jak1, Jak3, STAT3 and STAT5 correlated with the transition from an IL-2-dependent to an IL-2-independent phase in HTLV-1-transformed cells. Spontaneous phosphorylation of Jak2 and Jak3 has also been observed in T-cells transformed with HTLV-1 (Xu 1995). Leukemia cells obtained from ATL patients also showed constitutive activation of STATs (Takemoto 1997, Tsukada 2000). Takemoto *et al*.(Takemoto 1997) observed constitutive activation of STAT1, STAT3 and STAT5 in leukemic cells of ATL patients, and demonstrated the association of leukemic cell proliferation with constitutive JAK-STAT activity.

In addition, no gain-of-function mutations of the Jak1 and Jak3 in primary ATLL cells has been detected (Kameda 2010). These data are contrast to the results obtained from acute Tlymphoblastic leukemia (T-ALL). Flex *et al*. demonstrated that *JAK1* gene mutations occur in ALL and are more frequently observed among adult individuals with involvement of the T cell lineage (Flex 2008). The mutations promote gain of kinase function, and are associated with poor response to therapy and overall prognosis.

#### **2.1 Unique function of the Jak-STAT signaling pathway in HTLV-1-infected T-cells**

HTLV-1 infection up-regulates expression of the suppressor of cytokine signaling 1 (SOCS1). HTLV-1-induced SOCS1 inhibits the type I IFN antiviral response against HTLV-1 by

Constitutive Activation of the JAK/STAT

2006a, Tomita 2006b).

**transformed with HTLV-1**

And Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma 85

co-immunopreciptates with Jak3 in HTLV-1-transformed cell lines HUT102, MT2, MS9 and MS68. Phosphorylation of STAT5 and STAT3 are inhibited by cell treatment with the Src kinase inhibitor PP2 or by ectopic expression of a dominant negative Lyn kinase protein (Shuh 2011). Dequelin, a naturally occurring retinoid shows anti-proliferative effect on HTLV-1-transformed cells, MT-2 and KUT-1 in part through the down-regulation of survivin and constitutive phosphorylation of STAT3. In contrast, STAT5 phosphorylation is not affected by Deguelin (Ito 2010). roscovitine, an inhibitor of cyclin-dependent kinases (CDKs) inhibits STAT5 activity required for the survival of MT-2 cells. A dominant negative STAT5 expression induces apoptosis and reduces the abundance of an anti-apoptotic protein XIAP in MT-2 cells. In ChIP assay, interaction of STAT5, but not STAT1 with the XIAP promoter has been observed. Interaction of STAT5 and PDGF receptor is also prevented by roscovitine (Mohapatra 2003). Curcumin (diferuloylmethane), a naturally occurring yellow pigment isolated from the rhizomes of the plant *Curcuma longa*, induces apoptosis and anti-proliferative response in HTLV-1-transformed cells; MT-2, HUT102 and SLB-1. These responses are associated with inhibition of constitutive phosphorylation of Jak3, Tyk2, STAT3 and STAT5. Additionally, AP-1, especially JunD and NF-B activity in HTLV-1-transfromed T-cells and primary ATLL cells are also inhibited by curcumin (Tomita

In a clinical study, Berkowitz et al. reported a single institute open-label phase II trial of intravenous daclizumab, a humanized monoclonal antibody that binds specifically to the alpha (CD25) subunit of the high-affinity IL-2R in ATLL patients. No responses were observed in aggressive acute or lymphoma type of ATLL. Partial responses were observed

In addition, Tasocitinib (CP-690,550), a potent and selective Jak3 inhibitor is an orally active immunosuppressant undergoing clinical trials for the treatment of autoimmune diseases and transplant rejection. It is interesting to note that Tasocitinib (CP-690,550) inhibits proliferation of peripheral blood mononuclear cells (PBMCs) from patients with chronic and smoldering form of ATLL or with HAM/TSP that manifest constitutive Jak3/STAT5 activation. This agent prolongs the survival of transgenic mice bearing human CD8 T-cell leukemia with IL-15/IL-15R autocrine growth loop required for leukemia cell survival (Ju 2011). These results suggest clinical effect of CP-690,550 on chronic and smoldering ATLL.

STAT4 is a crucial mediator of IL-12-stimulated gene regulation (Jacobson 1995, Bacon 1995b). In fact, the development of type-1 helper T (Th1) cells and production of IFN-γ in response to IL-12 are disrupted in STAT4-deficient mice (Thierfelder 1996, Kaplan 1996). STAT4 is phosphorylated on tyrosine by Jak2 and Tyk2 (Bacon 1995a, Cho 1996). Moreover, IL-12 activates the p38/MKK6 signaling pathway that in turn phosphorylates STAT4 on serine (Visconti 2000). Activation of p38 and its upstream activator MKK6 is an important step for IL-12-induced STAT4 transcriptional activity (Visconti 2000, Zhang 2000). In fact, previous studies indicated that IFN-γ production is blocked by a p38 inhibitor (Zhang 2000, Rincon 1998). Transgenic mice expressing a dominant-negative p38 showed impaired Th1 differentiation (Rincon 1998). The expression of STAT4 is observed in limited types of tissues such as testis, spleen, lung, bone marrow, thymus and muscle (Zhong 1994, Yamamoto 1994). Several T-cell lines including EL4 and DA2 contain no

in 36% of patients with chronic and smoldering ATLL (Berkowitz JL 2010).

**2.1.2 Constitutive tyrosine and serine phosphorylation of STAT4 in T-cells**

targeting IRF3 for SOCS1-induced proteasome degradation (Oliere 2010). As an adaptor, SOCS1 brings target proteins to the elongin B/C-Cullin E3 ligase complex for ubiquitination. It may represent an immune evasion strategy and survival advantage to HTLV-1-infected cells. HTLV-1 inhibits IFN-induced phosphorylation of STAT2 and Tyk2 (Feng 2008). Zhang *et al*. further indicate that Tax interferes with IFN--induced JAK-STAT signaling by completion with STAT2 for CBP/p300 binding (Zhang 2008) (Fig2).

Fig. 2. Constitutive association of MyD88 with IRAK in HTLV-1-transformed T-cells.

The viral p12 protein from the pX open reading frame I (ORFI) activates Jak1/3 and STAT5, and decrease the IL-2-requirement for T-cell proliferation *via* binding to the cytoplasmic domain of IL-2R chain (Nicot 2001). Although the IL-2-Jak-STAT pathway is not associated with viral gene expression, viral RNA encapsidation, the maturation of the viral particle, cell-cell adherence or Gag polarization, p12 enhances viral transmission through activation of the IL-2-Jak-STAT pathway (Taylor 2009).

#### **2.1.1 Inhibition of the JAK-STAT signaling pathway in ATLL cells and HTLV-1 transformed T-cells; therapeutic approach**

Several recent studies reported inhibition of constitutive activation of the JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells. Src-related kinase Lyn

targeting IRF3 for SOCS1-induced proteasome degradation (Oliere 2010). As an adaptor, SOCS1 brings target proteins to the elongin B/C-Cullin E3 ligase complex for ubiquitination. It may represent an immune evasion strategy and survival advantage to HTLV-1-infected cells. HTLV-1 inhibits IFN-induced phosphorylation of STAT2 and Tyk2 (Feng 2008). Zhang *et al*. further indicate that Tax interferes with IFN--induced JAK-STAT

signaling by completion with STAT2 for CBP/p300 binding (Zhang 2008) (Fig2).

Fig. 2. Constitutive association of MyD88 with IRAK in HTLV-1-transformed T-cells.

**2.1.1 Inhibition of the JAK-STAT signaling pathway in ATLL cells and HTLV-1-**

of the IL-2-Jak-STAT pathway (Taylor 2009).

**transformed T-cells; therapeutic approach**

The viral p12 protein from the pX open reading frame I (ORFI) activates Jak1/3 and STAT5, and decrease the IL-2-requirement for T-cell proliferation *via* binding to the cytoplasmic domain of IL-2R chain (Nicot 2001). Although the IL-2-Jak-STAT pathway is not associated with viral gene expression, viral RNA encapsidation, the maturation of the viral particle, cell-cell adherence or Gag polarization, p12 enhances viral transmission through activation

Several recent studies reported inhibition of constitutive activation of the JAK-STAT signaling pathway in ATLL cells and HTLV-1-transformed T-cells. Src-related kinase Lyn co-immunopreciptates with Jak3 in HTLV-1-transformed cell lines HUT102, MT2, MS9 and MS68. Phosphorylation of STAT5 and STAT3 are inhibited by cell treatment with the Src kinase inhibitor PP2 or by ectopic expression of a dominant negative Lyn kinase protein (Shuh 2011). Dequelin, a naturally occurring retinoid shows anti-proliferative effect on HTLV-1-transformed cells, MT-2 and KUT-1 in part through the down-regulation of survivin and constitutive phosphorylation of STAT3. In contrast, STAT5 phosphorylation is not affected by Deguelin (Ito 2010). roscovitine, an inhibitor of cyclin-dependent kinases (CDKs) inhibits STAT5 activity required for the survival of MT-2 cells. A dominant negative STAT5 expression induces apoptosis and reduces the abundance of an anti-apoptotic protein XIAP in MT-2 cells. In ChIP assay, interaction of STAT5, but not STAT1 with the XIAP promoter has been observed. Interaction of STAT5 and PDGF receptor is also prevented by roscovitine (Mohapatra 2003). Curcumin (diferuloylmethane), a naturally occurring yellow pigment isolated from the rhizomes of the plant *Curcuma longa*, induces apoptosis and anti-proliferative response in HTLV-1-transformed cells; MT-2, HUT102 and SLB-1. These responses are associated with inhibition of constitutive phosphorylation of Jak3, Tyk2, STAT3 and STAT5. Additionally, AP-1, especially JunD and NF-B activity in HTLV-1-transfromed T-cells and primary ATLL cells are also inhibited by curcumin (Tomita 2006a, Tomita 2006b).

In a clinical study, Berkowitz et al. reported a single institute open-label phase II trial of intravenous daclizumab, a humanized monoclonal antibody that binds specifically to the alpha (CD25) subunit of the high-affinity IL-2R in ATLL patients. No responses were observed in aggressive acute or lymphoma type of ATLL. Partial responses were observed in 36% of patients with chronic and smoldering ATLL (Berkowitz JL 2010).

In addition, Tasocitinib (CP-690,550), a potent and selective Jak3 inhibitor is an orally active immunosuppressant undergoing clinical trials for the treatment of autoimmune diseases and transplant rejection. It is interesting to note that Tasocitinib (CP-690,550) inhibits proliferation of peripheral blood mononuclear cells (PBMCs) from patients with chronic and smoldering form of ATLL or with HAM/TSP that manifest constitutive Jak3/STAT5 activation. This agent prolongs the survival of transgenic mice bearing human CD8 T-cell leukemia with IL-15/IL-15R autocrine growth loop required for leukemia cell survival (Ju 2011). These results suggest clinical effect of CP-690,550 on chronic and smoldering ATLL.

#### **2.1.2 Constitutive tyrosine and serine phosphorylation of STAT4 in T-cells transformed with HTLV-1**

STAT4 is a crucial mediator of IL-12-stimulated gene regulation (Jacobson 1995, Bacon 1995b). In fact, the development of type-1 helper T (Th1) cells and production of IFN-γ in response to IL-12 are disrupted in STAT4-deficient mice (Thierfelder 1996, Kaplan 1996). STAT4 is phosphorylated on tyrosine by Jak2 and Tyk2 (Bacon 1995a, Cho 1996). Moreover, IL-12 activates the p38/MKK6 signaling pathway that in turn phosphorylates STAT4 on serine (Visconti 2000). Activation of p38 and its upstream activator MKK6 is an important step for IL-12-induced STAT4 transcriptional activity (Visconti 2000, Zhang 2000). In fact, previous studies indicated that IFN-γ production is blocked by a p38 inhibitor (Zhang 2000, Rincon 1998). Transgenic mice expressing a dominant-negative p38 showed impaired Th1 differentiation (Rincon 1998). The expression of STAT4 is observed in limited types of tissues such as testis, spleen, lung, bone marrow, thymus and muscle (Zhong 1994, Yamamoto 1994). Several T-cell lines including EL4 and DA2 contain no

Constitutive Activation of the JAK/STAT

(Takeuchi 2007).

And Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma 87

same study group reported that AZD1152, a selective inhibitor for Aurora B kinase had no

The TLR comprise a subfamily within the larger superfamily of interleukin (IL) receptors, based on similarity within their cytoplasmic regions (Dunne 2003, Matsushima 2007, McGettrick 2007, Takeda 2003) The extracellular region of the IL-1 receptors (IL-1Rs) possesses three immunoglobulin-like domains, those of TLRs are characterized by the presence of 16-28 leucine-rich repeats. Engagement of IL-1R or TLR with their cognate ligands causes an adaptor protein MyD88 to be recruited to the receptor complex, which, in turn, promotes its association with the IL-1R–associated kinase (IRAK) *via* an interaction between the respective death domains of each molecule. This is followed by autophosphorylation of IRAK that results in dissociation from the receptor complex and its subsequent interaction with tumor-necrosis-factor (TNF) receptor–associated factor-6 (TRAF-6). Emanating from TRAF-6, two signaling pathways diverge, one eventually leading to NF-B activation, and another to mitogen-activated protein (MAP) kinase activation

In this regard, our study demonstrated an alternative mechanism of NF-B activation through the TLR signaling cascade including MyD88 and IRAK in HTLV-1-–transformed Tcells and ATLL cells (Fig. 2). MyD88 and IRAK1 are constitutively active in HTLV-1 transformed T-cells, but not in HTLV-1-negative T-cells (Mizobe 2007). MyD88, originally isolated as a myeloid differentiation primary response gene product, possesses its Cterminal domain, which is highly homologous to the cytoplasmic regions of the TLR family of proteins (Dunne 2003, Takeda 2003). However, unlike members of the TLR family, MyD88 contains no transmembrane domain. MyD88 acts an adaptor molecule of most TLRs and receptors for IL-1 and IL-18 to recruit IRAK to the TLR complex, thereby regulating activation of various transcription factors involved in inflammatory responses, such as NF- B and C/EBP (NF-IL6) (Akira 2003a, Akira 2001, Akira 2003b, Boch 2003, Burns 1998,

Expression of a dominant negative MyD88 (MyD88dn) lacking its death domain (DD), MyD88dn induces apoptosis and anti-proliferative response in HTLV-1-transformed T-cells. In HTLV-1-transformed T-cells, MyD88dn protein expression inhibits constitutive activation of C/EBP (NF-IL6) and NF-B, and proinflamatory cytokine gene promoters such as IL-1, IFN- and TNF-. Furthermore, Tax synergistically activates NF-B with MyD88 (Mizobe 2007). The synergy may suggest ligand-independent activation of MyD88 in HTLV-1 transformed cells (Fig. 2). However, NF-B activation has been observed even in ATLL cells lacking detectable Tax expression. The mechanism for activation of NF-B in ATLL cells is not still clear. A recent study reported contribution of elevated CD30 expression to constitutive activation of NF-B in ATLL cells (Higuchi 2005). In this regard, the noncanonical pathway for NF-B activation, induced by B-cell activation factor (Claudio 2002, Kayagaki 2002), lymphotoxin- (Dejardin 2002, Saitoh 2002), CD40 (Coope 2002), TNF-like weak inducer of apoptosis (Saitoh 2003) or CD30 (Higuchi 2005) may be also involved in

In addition, MT-2 cells express TLR-1, 6 and 10 mRNA. Several recent reports have indicated unique expression profiles of TLRs on different subsets of T-cells. Gelman *et al*. (Gelman 2004) reported that TLR-3, -5 and -9 are expressed selectively on activated human CD4+ T cells, and that treatment of activated human CD4+ T-cells, with dsRNA synthetic analogs, poly(I:C) and CpGoligodeoxynucleotides (CpG DNA), directly enhance their

effect on NF-B activity in MT-4 and HUT102 cells (Tomita 2010).

Dunne 2003, Jefferies 2001, Muzio 2000, O'Neill 2003, Takeda 2003).

constitutive NF-B activation in ATLL cells (Hironaka 2004).

STAT4 transcripts (Yamamoto 1994). However, our study showed that tyrosinephosphorylated STAT4 was detected in HTLV-1-transformed cell lines. In addition, STAT4 protein was constitutively phosphorylated on serine as well as on tyrosine in HTLV-1-transformed cell lines (Higashi 2005).

The relevance of phosphorylation of serine in STAT4 has been recently reported. Serine phosphorylation of STAT4 is dispensable for nuclear translocation or DNA binding of STAT4, but is indispensable for its maximal transcriptional activity (Visconti 2000). Serine phosphorylation of STAT4 is required for IL-12-induced IFN-γ production and IL-12 mediated Th1 development, but not for IL-12-induced cell proliferation (Morinobu 2002). Furthermore, they have shown that serine phosphorylation of STAT4 is partially dependent on precedent tyrosine phosphorylation of STAT4, whereas tyrosine phosphorylation of STAT4 can be seen even in the absence of serine phosphorylation. In contrast, it has been shown that in leukemic cells from chronic lymphocytic leukemia patients, STAT1 and STAT3 are constitutively phosphorylated on serine, but not on tyrosine residue (Frank 1997). In the other leukemias such as AML and ALL, serine phosphorylation of the STATs was occasionally seen (Frank 1997, Hayakawa 1998). Thus, STATs may have selective effects on gene expression of leukemia cells in a manner dependent upon serine phosphorylation. We observed that IFN-γ, but not IL-12 or IFN-α was produced in HTLV-1-transformed cells.

#### **2.1.3 Constitutive association of MyD88 to IRAK in HTLV-1 -transformed cells**

Aberrant cytokine gene expression is a hallmark of ATLL cells (Franchini 1995, Grossman 1997, Kanno 1994, Mori 1999, Mori 1996a, Mori 1996b, Siekevitz 1987, Yamada 1996). The cytokine gene promoters possess enhancer elements for NF-B and/or C/EBP (NF-IL6) (Azimi 1998, Faggioli 1996, Mercurio 1997, Perkins 1997, Schmitz 1995, Washizu 1998). C/EBP (NF-IL6), β isoform of CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors (Tsukada 2011) was originally identified as a nuclear factor that binds to IL-1-responsive element in the *IL6* gene (Akira 1990). Moreover, inhibition of NF-kB activity results in enhanced apoptosis and growth suppression of primary ATLL cells and HTLV-1-transformed T-cells, indicating a central role for NF-B in their survival and proliferation. Antisense oligonucleotides to RelA/p65 inhibit Tax-transformed tumor cell growth (Kitajima 1992). Sodium salicylate and cyclopentenone prostaglandins suppress proliferation of Tax-transgenic mouse spleen cells (Portis 2001). Bay-7082, an inhibitor of IB phosphorylation induces apoptosis of HTLV-1-transformed T-cell lines and primary ATLL cells *via* reduced expression of the anti-apoptotic gene BCL-XL (Mori 2002). *Ex vivo*  treatment of PBMCs with dehydroxymethylepoxyquinomicin selectively purges HTLV-1 infected cells without toxicity to normal cells in HTLV-1 carriers (Watanabe 2005). More recently, activation of the classical pathway of NF-B by the HBZ has been reported (Zhao 2009). HBZ does not affect the alternative pathway of NF-B, but induces polyubiquitination and degradation of p65. Yasunaga *et al*. demonstrated that ubiquitin-specific peptidase USP20 deubiquitinates TRAF6 and Tax and suppresses Tax-induced NF-B activation (Yasunaga 2011). Several agents such as Bidens pilosa, a plant found in tropical and subtropical regions (Nakama 2011) and hippuristanol, an eukaryotic translation initiation inhibitor from the coral Isis hippuris (Tsumuraya 2011) also show inhibitory effect on ATLL cells through suppression of NF-B actitivty. On the other hand, pan-aurora kinase inhibitor has been shown to have anti-proliferative effect on HTLV-1-transformed T-cells and primary ATLL cells through the suppression of NF-B activity (Tomita 2009). However, the

STAT4 transcripts (Yamamoto 1994). However, our study showed that tyrosinephosphorylated STAT4 was detected in HTLV-1-transformed cell lines. In addition, STAT4 protein was constitutively phosphorylated on serine as well as on tyrosine in

The relevance of phosphorylation of serine in STAT4 has been recently reported. Serine phosphorylation of STAT4 is dispensable for nuclear translocation or DNA binding of STAT4, but is indispensable for its maximal transcriptional activity (Visconti 2000). Serine phosphorylation of STAT4 is required for IL-12-induced IFN-γ production and IL-12 mediated Th1 development, but not for IL-12-induced cell proliferation (Morinobu 2002). Furthermore, they have shown that serine phosphorylation of STAT4 is partially dependent on precedent tyrosine phosphorylation of STAT4, whereas tyrosine phosphorylation of STAT4 can be seen even in the absence of serine phosphorylation. In contrast, it has been shown that in leukemic cells from chronic lymphocytic leukemia patients, STAT1 and STAT3 are constitutively phosphorylated on serine, but not on tyrosine residue (Frank 1997). In the other leukemias such as AML and ALL, serine phosphorylation of the STATs was occasionally seen (Frank 1997, Hayakawa 1998). Thus, STATs may have selective effects on gene expression of leukemia cells in a manner dependent upon serine phosphorylation. We observed that IFN-γ, but not IL-12 or IFN-α

**2.1.3 Constitutive association of MyD88 to IRAK in HTLV-1 -transformed cells**

Aberrant cytokine gene expression is a hallmark of ATLL cells (Franchini 1995, Grossman 1997, Kanno 1994, Mori 1999, Mori 1996a, Mori 1996b, Siekevitz 1987, Yamada 1996). The cytokine gene promoters possess enhancer elements for NF-B and/or C/EBP (NF-IL6) (Azimi 1998, Faggioli 1996, Mercurio 1997, Perkins 1997, Schmitz 1995, Washizu 1998). C/EBP (NF-IL6), β isoform of CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors (Tsukada 2011) was originally identified as a nuclear factor that binds to IL-1-responsive element in the *IL6* gene (Akira 1990). Moreover, inhibition of NF-kB activity results in enhanced apoptosis and growth suppression of primary ATLL cells and HTLV-1-transformed T-cells, indicating a central role for NF-B in their survival and proliferation. Antisense oligonucleotides to RelA/p65 inhibit Tax-transformed tumor cell growth (Kitajima 1992). Sodium salicylate and cyclopentenone prostaglandins suppress proliferation of Tax-transgenic mouse spleen cells (Portis 2001). Bay-7082, an inhibitor of IB phosphorylation induces apoptosis of HTLV-1-transformed T-cell lines and primary ATLL cells *via* reduced expression of the anti-apoptotic gene BCL-XL (Mori 2002). *Ex vivo*  treatment of PBMCs with dehydroxymethylepoxyquinomicin selectively purges HTLV-1 infected cells without toxicity to normal cells in HTLV-1 carriers (Watanabe 2005). More recently, activation of the classical pathway of NF-B by the HBZ has been reported (Zhao 2009). HBZ does not affect the alternative pathway of NF-B, but induces polyubiquitination and degradation of p65. Yasunaga *et al*. demonstrated that ubiquitin-specific peptidase USP20 deubiquitinates TRAF6 and Tax and suppresses Tax-induced NF-B activation (Yasunaga 2011). Several agents such as Bidens pilosa, a plant found in tropical and subtropical regions (Nakama 2011) and hippuristanol, an eukaryotic translation initiation inhibitor from the coral Isis hippuris (Tsumuraya 2011) also show inhibitory effect on ATLL cells through suppression of NF-B actitivty. On the other hand, pan-aurora kinase inhibitor has been shown to have anti-proliferative effect on HTLV-1-transformed T-cells and primary ATLL cells through the suppression of NF-B activity (Tomita 2009). However, the

HTLV-1-transformed cell lines (Higashi 2005).

was produced in HTLV-1-transformed cells.

same study group reported that AZD1152, a selective inhibitor for Aurora B kinase had no effect on NF-B activity in MT-4 and HUT102 cells (Tomita 2010).

The TLR comprise a subfamily within the larger superfamily of interleukin (IL) receptors, based on similarity within their cytoplasmic regions (Dunne 2003, Matsushima 2007, McGettrick 2007, Takeda 2003) The extracellular region of the IL-1 receptors (IL-1Rs) possesses three immunoglobulin-like domains, those of TLRs are characterized by the presence of 16-28 leucine-rich repeats. Engagement of IL-1R or TLR with their cognate ligands causes an adaptor protein MyD88 to be recruited to the receptor complex, which, in turn, promotes its association with the IL-1R–associated kinase (IRAK) *via* an interaction between the respective death domains of each molecule. This is followed by autophosphorylation of IRAK that results in dissociation from the receptor complex and its subsequent interaction with tumor-necrosis-factor (TNF) receptor–associated factor-6 (TRAF-6). Emanating from TRAF-6, two signaling pathways diverge, one eventually leading to NF-B activation, and another to mitogen-activated protein (MAP) kinase activation (Takeuchi 2007).

In this regard, our study demonstrated an alternative mechanism of NF-B activation through the TLR signaling cascade including MyD88 and IRAK in HTLV-1-–transformed Tcells and ATLL cells (Fig. 2). MyD88 and IRAK1 are constitutively active in HTLV-1 transformed T-cells, but not in HTLV-1-negative T-cells (Mizobe 2007). MyD88, originally isolated as a myeloid differentiation primary response gene product, possesses its Cterminal domain, which is highly homologous to the cytoplasmic regions of the TLR family of proteins (Dunne 2003, Takeda 2003). However, unlike members of the TLR family, MyD88 contains no transmembrane domain. MyD88 acts an adaptor molecule of most TLRs and receptors for IL-1 and IL-18 to recruit IRAK to the TLR complex, thereby regulating activation of various transcription factors involved in inflammatory responses, such as NF- B and C/EBP (NF-IL6) (Akira 2003a, Akira 2001, Akira 2003b, Boch 2003, Burns 1998, Dunne 2003, Jefferies 2001, Muzio 2000, O'Neill 2003, Takeda 2003).

Expression of a dominant negative MyD88 (MyD88dn) lacking its death domain (DD), MyD88dn induces apoptosis and anti-proliferative response in HTLV-1-transformed T-cells. In HTLV-1-transformed T-cells, MyD88dn protein expression inhibits constitutive activation of C/EBP (NF-IL6) and NF-B, and proinflamatory cytokine gene promoters such as IL-1, IFN- and TNF-. Furthermore, Tax synergistically activates NF-B with MyD88 (Mizobe 2007). The synergy may suggest ligand-independent activation of MyD88 in HTLV-1 transformed cells (Fig. 2). However, NF-B activation has been observed even in ATLL cells lacking detectable Tax expression. The mechanism for activation of NF-B in ATLL cells is not still clear. A recent study reported contribution of elevated CD30 expression to constitutive activation of NF-B in ATLL cells (Higuchi 2005). In this regard, the noncanonical pathway for NF-B activation, induced by B-cell activation factor (Claudio 2002, Kayagaki 2002), lymphotoxin- (Dejardin 2002, Saitoh 2002), CD40 (Coope 2002), TNF-like weak inducer of apoptosis (Saitoh 2003) or CD30 (Higuchi 2005) may be also involved in constitutive NF-B activation in ATLL cells (Hironaka 2004).

In addition, MT-2 cells express TLR-1, 6 and 10 mRNA. Several recent reports have indicated unique expression profiles of TLRs on different subsets of T-cells. Gelman *et al*. (Gelman 2004) reported that TLR-3, -5 and -9 are expressed selectively on activated human CD4+ T cells, and that treatment of activated human CD4+ T-cells, with dsRNA synthetic analogs, poly(I:C) and CpGoligodeoxynucleotides (CpG DNA), directly enhance their

Constitutive Activation of the JAK/STAT

1168-75, 0301-472X.

survival. *Blood,* 99, 1, 252-7.

(ATL). *J Clin Oncol,* 28, 15s, suppl; abstr 8043.

*Biochem Biophys Res Commun,* 303, 2, 525-31, 0006-291X.

JE, Jr. (1999) Stat3 as an oncogene. *Cell,* 98, 3, 295-303.

*J Biol Chem,* 273, 20, 12203-9, 0021-9258..

0027-8424

399-404.

2474-88.

1551-7, 0022-1767..

And Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma 89

Azimi, N, Brown, K, Bamford, RN, Tagaya, Y, Siebenlist, U & Waldmann, TA (1998) Human

Bacon, CM, McVicar, DW, Ortaldo, JR, Rees, RC, O'Shea, JJ & Johnston, JA (1995a)

Bacon, CM, Petricoin, EF, 3rd, Ortaldo, JR, Rees, RC, Larner, AC, Johnston, JA & O'Shea, JJ

Benekli, M, Xia, Z, Donohue, KA, Ford, LA, Pixley, LA, Baer, MR, Baumann, H & Wetzler,

Berkowitz JL, JJ, Stewart DM, Fioravanti S, Jaffe ES, Fleisher TA, Urquhart N,Wharfe JH,

Boch, JA, Yoshida, Y, Koyama, Y, Wara-Aswapati, N, Peng, H, Unlu, S & Auron, PE (2003)

Bowman, T, Garcia, R, Turkson, J & Jove, R (2000) STATs in oncogenesis. *Oncogene,* 19, 21,

Bromberg, JF, Wrzeszczynska, MH, Devgan, G, Zhao, Y, Pestell, RG, Albanese, C & Darnell,

Burns, K, Martinon, F, Esslinger, C, Pahl, H, Schneider, P, Bodmer, JL, Di Marco, F, French, L

Carlesso, N, Frank, DA & Griffin, JD (1996) Tyrosyl phosphorylation and DNA binding

hematopoietic cell lines transformed by Bcr/Abl. *J Exp Med,* 183, 3, 811-20. Caron, G, Duluc, D, Fremaux, I, Jeannin, P, David, C, Gascan, H & Delneste, Y (2005) Direct

Chen, J, Petrus, M, Bryant, BR, Phuc Nguyen, V, Stamer, M, Goldman, CK, Bamford, R,

Cho, SS, Bacon, CM, Sudarshan, C, Rees, RC, Finbloom, D, Pine, R & O'Shea, JJ (1996)

induced tyrosine and serine phosphorylation.  *Blood,* 111, 10, 5163-72, 1528-0020.

human lymphocytes. *Proc Natl Acad Sci U S A,* 92, 16, 7307-11.

primary adult T-cell leukemia cells and its clinical implications. *Exp Hematol,* 27, 7,

T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-B site. *Proc Natl Acad Sci U S A,* 95, 5, 2452-7,

Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. *J Exp Med,* 181, 1,

(1995b) Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in

M (2002) Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free

Waldmann TA, Morris JC (2010) Phase II trial of daclizumab in human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma

Characterization of a cascade of protein interactions initiated at the IL-1 receptor.

& Tschopp, J (1998) MyD88, an adapter protein involved in interleukin-1 signaling.

activity of signal transducers and activators of transcription (STAT) proteins in

stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN- production by memory CD4+ T cells. *J Immunol,* 175, 3,

Morris, JC, Janik, JE & Waldmann, TA (2008) Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells

Activation of STAT4 by IL-12 and IFN-: evidence for the involvement of ligand-

survival without affecting proliferation. A TLR-5 ligand flagellin and a TLR7/8 ligand R-848 promotes proliferation and to upregulate production of IFN-, IL-8 and IL-10, but not IL-4, in human CD4+ T-cells (Caron 2005). In particular, engagement of TLR-5 with flagellin enhances the suppressive capacity and FOXP3 expression in Treg cells (Crellin 2005). Direct modulation of Treg function by TLR2 ligands has been also reported (Oberg 2010). On the other hand, IRF-5 (P68) with a mutation of Ala to Pro at amino acid 68 (G202C; position relative to translation start codon) suppresses TLR-mediated IL-6 and IL-12p40 induction. The mutation has been identified in peripheral blood of ATLL patients (Yang 2009).

A more recent report has emphasized the significance of MyD88 in the pathogenesis and therapeutic approach for lymphoma. Ngo *et al*. identified a single leucine-to-proline substitution at amino acid position 265 of MyD88 protein (L265P) in 29% of activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) biopsy samples. This mutation occurs at an evolutionally invariant residue in the hydrophobic core and is rare or absent in the other DLBCL subtypes. They further demonstrated that in ABC DLBCL with L265P mutation, MyD88 L265P rescued the cell after MyD88 knockdown, but wild-type MyD88 was ineffective, showing that the L265P is a gain-of-function mutation and ABC DLBCL with L265P mutation depends upon the MyD88 signaling pathway.  Moreover, in ABC DLBCL cell lines, MyD88 knockdown diminishes the secretion of IL-6 and IL-10 and phosphorylation of STAT3 (Ngo 2011).

#### **3. Conclusion**

Investigations have led to the demonstration of the several regulatory mechanisms presented in this review. Recent reports have provided detailed insight into the crucial functional roles of JAK-STAT and MyD88-TLR in ATLL. An important goal of such approaches would be the identification of unique targets for clinical intervention. The fact that the two signaling pathway are attractive targets for leukemia therapies further argues the importance of constitutive activation of these factors in ATLL cells.

#### **4. References**

Akira, S (1997) IL-6-regulated transcription factors. *Int J Biochem Cell Biol,* 29, 12, 1401-18.

survival without affecting proliferation. A TLR-5 ligand flagellin and a TLR7/8 ligand R-848 promotes proliferation and to upregulate production of IFN-, IL-8 and IL-10, but not IL-4, in human CD4+ T-cells (Caron 2005). In particular, engagement of TLR-5 with flagellin enhances the suppressive capacity and FOXP3 expression in Treg cells (Crellin 2005). Direct modulation of Treg function by TLR2 ligands has been also reported (Oberg 2010). On the other hand, IRF-5 (P68) with a mutation of Ala to Pro at amino acid 68 (G202C; position relative to translation start codon) suppresses TLR-mediated IL-6 and IL-12p40 induction.

A more recent report has emphasized the significance of MyD88 in the pathogenesis and therapeutic approach for lymphoma. Ngo *et al*. identified a single leucine-to-proline substitution at amino acid position 265 of MyD88 protein (L265P) in 29% of activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) biopsy samples. This mutation occurs at an evolutionally invariant residue in the hydrophobic core and is rare or absent in the other DLBCL subtypes. They further demonstrated that in ABC DLBCL with L265P mutation, MyD88 L265P rescued the cell after MyD88 knockdown, but wild-type MyD88 was ineffective, showing that the L265P is a gain-of-function mutation and ABC DLBCL with L265P mutation depends upon the MyD88 signaling pathway.  Moreover, in ABC DLBCL cell lines, MyD88 knockdown diminishes the secretion of IL-6 and IL-10 and

Investigations have led to the demonstration of the several regulatory mechanisms presented in this review. Recent reports have provided detailed insight into the crucial functional roles of JAK-STAT and MyD88-TLR in ATLL. An important goal of such approaches would be the identification of unique targets for clinical intervention. The fact that the two signaling pathway are attractive targets for leukemia therapies further argues

Akira, S (1997) IL-6-regulated transcription factors. *Int J Biochem Cell Biol,* 29, 12, 1401-18. Akira, S (2003) Toll-like receptor signaling. *J Biol Chem,* 278, 40, 38105-8, 0021-9258.

Akira, S, Isshiki, H, Sugita, T, Tanabe, O, Kinoshita, S, Nishio, Y, Nakajima, T, Hirano, T &

Akira, S, Takeda, K & Kaisho, T (2001) Toll-like receptors: critical proteins linking innate and

Akira, S, Yamamoto, M & Takeda, K (2003) Role of adapters in Toll-like receptor signalling.

Arima, N, Hidaka, S, Fujiwara, H, Matsushita, K, Ohtsubo, H, Arimura, K, Kukita, T,

Arima, N, Matsushita, K, Obata, H, Ohtsubo, H, Fujiwara, H, Arimura, K, Kukita, T, Suruga,

Kishimoto, T (1990) A nuclear factor for IL-6 expression (NF-IL6) is a member of a

Fukumori, J & Tanaka, H (1996) Relation of autonomous and interleukin-2 responsive growth of leukemic cells to survival in adult T-cell leukemia. *Blood,* 87,

Y, Wakamatsu, S, Hidaka, S & Tei, C (1999) NF-B involvement in the activation of

the importance of constitutive activation of these factors in ATLL cells.

C/EBP family. *EMBO J,* 9, 6, 1897-906, 0261-4189.

*Biochem Soc Trans,* 31, Pt 3, 637-42, 0300-5127.

7, 2900-4, 0006-4971.

acquired immunity. *Nat Immunol,* 2, 8, 675-80, 1529-2908.

The mutation has been identified in peripheral blood of ATLL patients (Yang 2009).

phosphorylation of STAT3 (Ngo 2011).

**3. Conclusion**

**4. References**

primary adult T-cell leukemia cells and its clinical implications. *Exp Hematol,* 27, 7, 1168-75, 0301-472X.

Constitutive Activation of the JAK/STAT

11, 1724-30.

And Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma 91

Frank, DA & Varticovski, L (1996) BCR/abl leads to the constitutive activation of Stat

Geleziunas, R, Ferrell, S, Lin, X, Mu, Y, Cunningham, ET, Jr., Grant, M, Connelly, MA,

Gelman, AE, Zhang, J, Choi, Y & Turka, LA (2004) Toll-like receptor ligands directly promote activated CD4+ T cell survival. *J Immunol,* 172, 10, 6065-73, 0022-1767. Gouilleux-Gruart, V, Gouilleux, F, Desaint, C, Claisse, JF, Capiod, JC, Delobel, J, Weber-

Grossman, WJ & Ratner, L (1997) Cytokine expression and tumorigenicity of large granular

Harhaj, EW & Sun, SC (1999) IKK serves as a docking subunit of the IB kinase (IKK) and

Hayakawa, F, Towatari, M, Iida, H, Wakao, H, Kiyoi, H, Naoe, T & Saito, H (1998)

Higuchi, M, Matsuda, T, Mori, N, Yamada, Y, Horie, R, Watanabe, T, Takahashi, M, Oie, M

possible role in constitutive NF-B activation. *Retrovirology,* 2, 29, 1742-4690. Hironaka, N, Mochida, K, Mori, N, Maeda, M, Yamamoto, N & Yamaoka, S (2004) Tax-

Huang, GJ, Zhang, ZQ & Jin, DY (2002) Stimulation of IKK- oligomerization by the human T-cell leukemia virus oncoprotein Tax. *FEBS Lett,* 531, 3, 494-8, 0014-5793. Ihle, JN (2001) The Stat family in cytokine signaling. *Curr Opin Cell Biol,* 13, 2, 211-7.

Ito, S, Oyake, T, Murai, K & Ishida, Y (2010) Deguelin suppresses cell proliferation via the

Jacobson, NG, Szabo, SJ, Weber-Nordt, RM, Zhong, Z, Schreiber, RD, Darnell, JE, Jr. &

Jefferies, C, Bowie, A, Brady, G, Cooke, EL, Li, X & O'Neill, LA (2001) Transactivation by the

in primary acute myelogenous leukaemia. *Br J Haematol,* 101, 3, 521-8. Higashi, T, Tsukada, J, Yoshida, Y, Mizobe, T, Mouri, F, Minami, Y, Morimoto, H & Tanaka,

transformed with HTLV-I. *Genes Cells,* 10, 12, 1153-62, 1356-9597.

cellular kinases. *Mol Cell Biol,* 18, 9, 5157-65, 0270-7306.

acute leukemia patients. *Blood,* 87, 5, 1692-7.

*Biol Chem,* 274, 33, 22911-4, 0021-9258.

*Neoplasia,* 6, 3, 266-78, 1522-8002.

and Stat4. *J Exp Med,* 181, 5, 1755-62.

0270-7306.

leukemia virus type I. *Blood,* 90, 2, 783-94, 0006-4971.

transformed T cells. *Leuk Res,* 34, 3, 352-7, 1873-5835.

proteins, and shares an epitope with tyrosine phosphorylated Stats. *Leukemia,* 10,

Hambor, JE, Marcu, KB & Greene, WC (1998) Human T-cell leukemia virus type 1 Tax induction of NF-B involves activation of the IB kinase (IKK) and IKK

Nordt, R, Dusanter-Fourt, I, Dreyfus, F, Groner, B & Prin, L (1996) STAT-related transcription factors are constitutively activated in peripheral blood cells from

lymphocytic leukemia cells from mice transgenic for the tax gene of human T-cell

mediates interaction of IKK with the human T-cell leukemia virus Tax protein. *J*

Differential constitutive activation between STAT-related proteins and MAP kinase

Y (2005) Constitutive tyrosine and serine phosphorylation of STAT4 in T-cells

& Fujii, M (2005) Elevated expression of CD30 in adult T-cell leukemia cell lines:

independent constitutive IB kinase activation in adult T-cell leukemia cells.

inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-

Murphy, KM (1995) Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3

p65 subunit of NF-B in response to interleukin-1 (IL-1) involves MyD88, IL-1 receptor-associated kinase 1, TRAF-6, and Rac1. *Mol Cell Biol,* 21, 14, 4544-52,

Claudio, E, Brown, K, Park, S, Wang, H & Siebenlist, U (2002) BAFF-induced NEMO-

Coffer, PJ, Koenderman, L & de Groot, RP (2000) The role of STATs in myeloid

Coope, HJ, Atkinson, PG, Huhse, B, Belich, M, Janzen, J, Holman, MJ, Klaus, GG, Johnston,

Crellin, NK, Garcia, RV, Hadisfar, O, Allan, SE, Steiner, TS & Levings, MK (2005) Human

Danial, NN, Pernis, A & Rothman, PB (1995) Jak-STAT signaling induced by the v-abl

Dejardin, E, Droin, NM, Delhase, M, Haas, E, Cao, Y, Makris, C, Li, ZW, Karin, M, Ware, CF

Faggioli, L, Costanzo, C, Merola, M, Bianchini, E, Furia, A, Carsana, A & Palmieri, M (1996)

Feng, X & Ratner, L (2008) Human T-cell leukemia virus type 1 blunts signaling by

Flex, E, Petrangeli, V, Stella, L, Chiaretti, S, Hornakova, T, Knoops, L, Ariola, C, Fodale, V,

Franchini, G (1995) Molecular mechanisms of human T-cell leukemia/lymphotropic virus

Franchini, G, Wong-Staal, F & Gallo, RC (1984) Human T-cell leukemia virus (HTLV-I)

Frank, DA, Mahajan, S & Ritz, J (1997) B lymphocytes from patients with chronic

breast carcinoma cell line. *Eur J Biochem,* 239, 3, 624-31, 0014-2956.

interferon . *Virology,* 374, 1, 210-6, 0042-6822.

leukemia. *J Exp Med,* 205, 4, 751-8, 1540-9538.

type I infection. *Blood,* 86, 10, 3619-39, 0006-4971.

*Natl Acad Sci U S A,* 81, 19, 6207-11, 0027-8424.

differentiation and leukemia. *Oncogene,* 19, 21, 2511-22.

Darnell, JE, Jr. (1997) STATs and gene regulation. *Science,* 277, 5332, 1630-5.

1529-2908.

1525-8882.

100, 12, 3140-8.

21, 20, 5375-85, 0261-4189.

175, 12, 8051-9, 0022-1767.

oncogene. *Science,* 269, 5232, 1875-7.

independent processing of NF-B2 in maturing B cells. *Nat Immunol,* 3, 10, 958-65,

LH & Ley, SC (2002) CD40 regulates the processing of NF-B2 p100 to p52. *EMBO J,*

CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. *J Immunol,*

& Green, DR (2002) The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-B pathways. *Immunity,* 17, 4, 525-35, 1074-7613. Dunne, A & O'Neill, LA (2003) The interleukin-1 receptor/Toll-like receptor superfamily:

signal transduction during inflammation and host defense. *Sci STKE,* 2003, 171, re3,

Nuclear factor B (NF-B), nuclear factor interleukin-6 (NFIL-6 or C/EBP) and nuclear factor interleukin-6(NFIL6- or C/EBP) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human

Clappier, E, Paoloni, F, Martinelli, S, Fragale, A, Sanchez, M, Tavolaro, S, Messina, M, Cazzaniga, G, Camera, A, Pizzolo, G, Tornesello, A, Vignetti, M, Battistini, A, Cave, H, Gelb, BD, Renauld, JC, Biondi, A, Constantinescu, SN, Foa, R & Tartaglia, M (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic

transcripts in fresh and cultured cells of patients with adult T-cell leukemia. *Proc*

lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. *J Clin Invest,*

Constitutive Activation of the JAK/STAT

0008-5472.

2360-8, 0006-4971.

99, 19, 12281-6.

And Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma 93

Mizobe, T, Tsukada, J, Higashi, T, Mouri, F, Matsuura, A, Tanikawa, R, Minami, Y, Yoshida,

Mohapatra, S, Chu, B, Wei, S, Djeu, J, Epling-Burnette, PK, Loughran, T, Jove, R & Pledger,

Mori, N, Fujii, M, Ikeda, S, Yamada, Y, Tomonaga, M, Ballard, DW & Yamamoto, N (1999)

Mori, N, Gill, PS, Mougdil, T, Murakami, S, Eto, S & Prager, D (1996) Interleukin-10 gene

Morinobu, A, Gadina, M, Strober, W, Visconti, R, Fornace, A, Montagna, C, Feldman, GM,

Muzio, M, Polentarutti, N, Bosisio, D, Manoj Kumar, PP & Mantovani, A (2000) Toll-like receptor family and signalling pathway. *Biochem Soc Trans,* 28, 5, 563-6, 0300-5127. Nakama, S, Ishikawa, C, Nakachi, S & Mori, N (2011) Anti-adult T-cell leukemia effects of

Ngo, VN, Young, RM, Schmitz, R, Jhavar, S, Xiao, W, Lim, KH, Kohlhammer, H, Xu, W,

mutations in human lymphoma. *Nature,* 470, 7332, 115-9, 1476-4687 . Nicot, C, Mulloy, JC, Ferrari, MG, Johnson, JM, Fu, K, Fukumoto, R, Trovato, R, Fullen, J,

human peripheral blood mononuclear cells. *Blood,* 98, 3, 823-9, 0006-4971. O'Neill, LA (2003) The role of MyD88-like adapters in Toll-like receptor signal transduction.

Oberg, HH, Ly, TT, Ussat, S, Meyer, T, Kabelitz, D & Wesch, D (2010) Differential but direct

Ohashi, T, Masuda, M & Ruscetti, SK (1995) Induction of sequence-specific DNA-binding factors by erythropoietin and the spleen focus-forming virus. *Blood,* 85, 6, 1454-62. Oliere, S, Hernandez, E, Lezin, A, Arguello, M, Douville, R, Nguyen, TL, Olindo, S,

expression in adult T-cell leukemia. *Blood,* 88, 3, 1035-45, 0006-4971. Mori, N & Prager, D (1996) Transactivation of the interleukin-1alpha promoter by human Tcell leukemia virus type I and type II Tax proteins. *Blood,* 87, 8, 3410-7, 0006-4971. Mori, N, Yamada, Y, Ikeda, S, Yamasaki, Y, Tsukasaki, K, Tanaka, Y, Tomonaga, M,

leukemia cells. *Blood,* 100, 5, 1828-34, 0006-4971.

Bidens pilosa. *Int J Oncol,* 38, 4, 1163-73, 1791-2423.

*Biochem Soc Trans,* 31, Pt 3, 643-7, 0300-5127.

ligands. *J Immunol,* 184, 9, 4733-40, 1550-6606.

transformed T cells. *Exp Hematol,* 35, 12, 1812-22, 0301-472X.

Y & Tanaka, Y (2007) Constitutive association of MyD88 to IRAK in HTLV-I-

WJ (2003) Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. *Cancer Res,* 63, 23, 8523-30,

Constitutive activation of NF-B in primary adult T-cell leukemia cells. *Blood,* 93, 7,

Yamamoto, N & Fujii, M (2002) Bay 11-7082 inhibits transcription factor NF-B and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell

Nishikomori, R & O'Shea, JJ (2002) STAT4 serine phosphorylation is critical for IL-12-induced IFN- production but not for cell proliferation. *Proc Natl Acad Sci U S A,*

Yang, Y, Zhao, H, Shaffer, AL, Romesser, P, Wright, G, Powell, J, Rosenwald, A, Muller-Hermelink, HK, Ott, G, Gascoyne, RD, Connors, JM, Rimsza, LM, Campo, E, Jaffe, ES, Delabie, J, Smeland, EB, Fisher, RI, Braziel, RM, Tubbs, RR, Cook, JR, Weisenburger, DD, Chan, WC & Staudt, LM (2011) Oncogenically active MYD88

Leonard, WJ & Franchini, G (2001) HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary

abolishment of human regulatory T cell suppressive capacity by various TLR2

Panelatti, G, Kazanji, M, Wilkinson, P, Sekaly, RP, Cesaire, R & Hiscott, J (2010)

Jin, DY, Giordano, V, Kibler, KV, Nakano, H & Jeang, KT (1999) Role of adapter function in

interacts directly with IB kinase . *J Biol Chem,* 274, 25, 17402-5, 0021-9258. Ju, W, Zhang, M, Jiang, JK, Thomas, CJ, Oh, U, Bryant, BR, Chen, J, Sato, N, Tagaya, Y,

Kanno, T, Brown, K, Franzoso, G & Siebenlist, U (1994) Kinetic analysis of human T-cell

Kaplan, MH, Sun, YL, Hoey, T & Grusby, MJ (1996) Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. *Nature,* 382, 6587, 174-7. Kayagaki, N, Yan, M, Seshasayee, D, Wang, H, Lee, W, French, DM, Grewal, IS, Cochran,

Kitajima, I, Shinohara, T, Bilakovics, J, Brown, DA, Xu, X & Nerenberg, M (1992) Ablation of

Leonard, WJ & O'Shea, JJ (1998) Jaks and STATs: biological implications. *Annu Rev Immunol,*

Levy, DE & Gilliland, DG (2000) Divergent roles of STAT1 and STAT5 in malignancy as

Lin, TS, Mahajan, S & Frank, DA (2000) STAT signaling in the pathogenesis and treatment of

Maeda, M, Arima, N, Daitoku, Y, Kashihara, M, Okamoto, H, Uchiyama, T, Shirono, K,

Matsushima, N, Tanaka, T, Enkhbayar, P, Mikami, T, Taga, M, Yamada, K & Kuroki, Y

McGettrick, AF & O'Neill, LA (2007) Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. *Br J Haematol,* 139, 2, 185-93, 0007-1048. Mercurio, F, Zhu, H, Murray, BW, Shevchenko, A, Bennett, BL, Li, J, Young, DB, Barbosa, M,

kinases essential for NF-B activation. *Science,* 278, 5339, 860-6, 0036-8075. Migone, TS, Lin, JX, Cereseto, A, Mulloy, JC, O'Shea, JJ, Franchini, G & Leonard, WJ (1995)

Matsuoka, M, Hattori, T, Takatsuki, K & et al. (1987) Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia. *Blood,* 70, 5, 1407-

(2007) Comparative sequence analysis of leucine-rich repeats (LRRs) within

Mann, M, Manning, A & Rao, A (1997) IKK-1 and IKK-2: cytokine-activated IB

Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.

promotes processing of NF-B2. *Immunity,* 17, 4, 515-24, 1074-7613.

revealed by gene disruptions in mice. *Oncogene,* 19, 21, 2505-10.

vertebrate toll-like receptors. *BMC Genomics,* 8, 124, 1471-2164.

NF-B. *Science,* 258, 5089, 1792-5, 0036-8075.

leukemias. *Oncogene,* 19, 21, 2496-504.

patients with ATL and HAM/TSP. *Blood,* 117, 6, 1938-46, 1528-0020. Kameda, T, Shide, K, Shimoda, HK, Hidaka, T, Kubuki, Y, Katayose, K, Taniguchi, Y,

leukemia/lymphoma. *Int J Hematol,* 92, 2, 320-5, 1865-3774.

51, 0270-7306.

16, 293-322.

11, 0006-4971.

*Science,* 269, 5220, 79-81.

oncoprotein-mediated activation of NF-B. Human T-cell leukemia virus type I Tax

Morris, JC, Janik, JE, Jacobson, S & Waldmann, TA (2011) CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from

Sekine, M, Kamiunntenn, A, Maeda, K, Nagata, K, Matsunaga, T & Shimoda, K (2010) Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell

leukemia virus type I Tax-mediated activation of NF-B. *Mol Cell Biol,* 14, 10, 6443-

AG, Gordon, NC, Yin, J, Starovasnik, MA & Dixit, VM (2002) BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and

transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of

Constitutive Activation of the JAK/STAT

cells. *Nature,* 382, 6587, 171-4.

*Res,* 30, 3, 313-21, 0145-2126.

127, 7, 1584-94, 1097-0215 .

cells. *Int J Cancer,* 118, 3, 765-72, 0020-7136.

activity. *Int J Cancer,* 124, 11, 2607-15, 1097-0215.

*Pharmacol,* 81, 6, 713-22, 1873-2968.

*Immunogenetics,* 48, 1, 1-7, 0093-7711 .

2, 169-76, 0007-1048 .

lines. *Blood,* 88, 3, 809-16.

of LIL-Stat in adult T-cell leukemia cells. *Blood,* 95, 8, 2715-8.

And Toll-Like Receptor Signaling Pathways in Adult T-Cell Leukemia/Lymphoma 95

Tomita, M, Kawakami, H, Uchihara, JN, Okudaira, T, Masuda, M, Takasu, N, Matsuda, T,

Tomita, M, Kawakami, H, Uchihara, JN, Okudaira, T, Masuda, M, Takasu, N, Matsuda, T,

Tomita, M, Tanaka, Y & Mori, N (2010) Aurora kinase inhibitor AZD1152 negatively affects

Tomita, M, Toyota, M, Ishikawa, C, Nakazato, T, Okudaira, T, Matsuda, T, Uchihara, JN,

Tsukada, J, Toda, Y, Misago, M, Tanaka, Y, Auron, PE & Eto, S (2000) Constitutive activation

Tsukada, J, Yoshida, Y, Kominato, Y & Auron, PE (2011) The CCAAT/enhancer (C/EBP)

Ueda, M, Imada, K, Imura, A, Koga, H, Hishizawa, M & Uchiyama, T (2005) Expression of

Visconti, R, Gadina, M, Chiariello, M, Chen, EH, Stancato, LF, Gutkind, JS & O'Shea, JJ

Watanabe, M, Ohsugi, T, Shoda, M, Ishida, T, Aizawa, S, Maruyama-Nagai, M, Utsunomiya,

Weber-Nordt, RM, Egen, C, Wehinger, J, Ludwig, W, Gouilleux-Gruart, V, Mertelsmann, R

therapy of adult T-cell leukemia. *Blood,* 106, 7, 2462-71, 0006-4971.

serine phosphorylation and transcriptional activity. *Blood,* 96, 5, 1844-52. Washizu, J, Nishimura, H, Nakamura, N, Nimura, Y & Yoshikai, Y (1998) The NF-B

regulated system for gene regulation. *Cytokine,* 54, 1, 6-19, 1096-0023. Tsumuraya, T, Ishikawa, C, Machijima, Y, Nakachi, S, Senba, M, Tanaka, J & Mori, N (2011)

Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T

Ohta, T, Tanaka, Y & Mori, N (2006a) Curcumin suppresses constitutive activation of AP-1 by downregulation of JunD protein in HTLV-1-infected T-cell lines. *Leuk*

Ohta, T, Tanaka, Y, Ohshiro, K & Mori, N (2006b) Curcumin (diferuloylmethane) inhibits constitutive active NF-B, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia

the growth and survival of HTLV-1-infected T lymphocytes in vitro. *Int J Cancer,*

Taira, N, Ohshiro, K, Senba, M, Tanaka, Y, Ohshima, K, Saya, H, Tokino, T & Mori, N (2009) Overexpression of Aurora A by loss of CHFR gene expression increases the growth and survival of HTLV-1-infected T cells through enhanced NF-B

family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-

Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. *Biochem*

functional interleukin-21 receptor on adult T-cell leukaemia cells. *Br J Haematol,* 128,

(2000) Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4

binding site is essential for transcriptional activation of the IL-15 gene.

A, Koga, S, Yamada, Y, Kamihira, S, Okayama, A, Kikuchi, H, Uozumi, K, Yamaguchi, K, Higashihara, M, Umezawa, K, Watanabe, T & Horie, R (2005) Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-B, as a strategy for chemoprevention and

& Finke, J (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell

HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). *PLoS Pathog,* 6, 11, e1001177, 1553-7374.

Portis, T, Harding, JC & Ratner, L (2001) The contribution of NF-B activity to spontaneous

Rincon, M, Enslen, H, Raingeaud, J, Recht, M, Zapton, T, Su, MS, Penix, LA, Davis, RJ &

Saitoh, T, Nakano, H, Yamamoto, N & Yamaoka, S (2002) Lymphotoxin-beta receptor

Saitoh, T, Nakayama, M, Nakano, H, Yagita, H, Yamamoto, N & Yamaoka, S (2003) TWEAK

Schmitz, ML & Baeuerle, PA (1995) Multi-step activation of NF-B/Rel transcription factors.

Shuai, K, Halpern, J, ten Hoeve, J, Rao, X & Sawyers, CL (1996) Constitutive activation of

Shuh, M, Morse, BA, Heidecker, G & Derse, D (2011) Association of SRC-related kinase lyn

Siekevitz, M, Feinberg, MB, Holbrook, N, Wong-Staal, F & Greene, WC (1987) Activation of

Spiekermann, K, Biethahn, S, Wilde, S, Hiddemann, W & Alves, F (2001) Constitutive

Takeda, K, Kaisho, T & Akira, S (2003) Toll-like receptors. *Annu Rev Immunol,* 21, 335-76,

Takemoto, S, Mulloy, JC, Cereseto, A, Migone, TS, Patel, BK, Matsuoka, M, Yamaguchi, K,

Takeuchi, O & Akira, S (2007) Signaling pathways activated by microorganisms. *Curr Opin*

Taylor, JM, Brown, M, Nejmeddine, M, Kim, KJ, Ratner, L, Lairmore, M & Nicot, C (2009)

Thierfelder, WE, van Deursen, JM, Yamamoto, K, Tripp, RA, Sarawar, SR, Carson, RT,

cytokine signaling 1 (SOCS1). *PLoS Pathog,* 6, 11, e1001177, 1553-7374. Perkins, ND (1997) Achieving transcriptional specificity with NF-B. *Int J Biochem Cell Biol,*

29, 12, 1433-48, 1357-2725.

278, 38, 36005-12, 0021-9258.

*Immunobiology,* 193, 2-4, 116-27, 0171-2985.

cells. *J Virol,* 85, 9, 4623-7, 1098-5514 .

*Sci U S A,* 84, 15, 5389-93, 0027-8424.

*Cell Biol,* 19, 2, 185-91, 0955-0674.

*Virol,* 83, 22, 11467-76, 1098-5514 .

*Haematol,* 67, 2, 63-71.

0732-0582.

13897-902.

5793.

2, 247-54.

induced tumors. *Blood,* 98, 4, 1200-8, 0006-4971.

p38 MAP kinase signaling pathway. *Embo J,* 17, 10, 2817-29.

HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of

proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-

Flavell, RA (1998) Interferon- expression by Th1 effector T cells mediated by the

mediates NEMO-independent NF-B activation. *FEBS Lett,* 532, 1-2, 45-51, 0014-

induces NF-B2 p100 processing and long lasting NF-B activation. *J Biol Chem,*

STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. *Oncogene,* 13,

with the interleukin-2 receptor and its role in maintaining constitutive phosphorylation of Jak/STAT in human T-cell leukemia virus type 1-transformed T

interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the transactivator (tat) gene product of human T-cell leukemia virus, type I. *Proc Natl Acad*

activation of STAT transcription factors in acute myelogenous leukemia. *Eur J*

Takatsuki, K, Kamihira, S, White, JD, Leonard, WJ, Waldmann, T & Franchini, G (1997) Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. *Proc Natl Acad Sci U S A,* 94, 25,

Novel role for interleukin-2 receptor-Jak signaling in retrovirus transmission. *J*

Sangster, MY, Vignali, DA, Doherty, PC, Grosveld, GC & Ihle, JN (1996)

Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. *Nature,* 382, 6587, 171-4.

**1. Introduction**

shed light on the role of Ikaros in T-cell leukemia.

**2. Structure and function of Ikaros**

**2.1 Molecular structure of Ikaros 2.1.1 DNA-binding domain**

**6**

**Ikaros in T-Cell Leukemia**

Sinisa Dovat1 and Kimberly J. Payne2

*2Loma Linda University United States of America*

*1Pennsylvania State University College of Medicine*

Although extensive clinical data have established that the loss of Ikaros tumor suppressor activity *via* genetic inactivation is a major contributor to leukemogenesis leading to B-cell ALL, less is known about the role of Ikaros in T-cell leukemia. The T-cell malignancies observed in Ikaros-deficient mice suggest that Ikaros is likely to function as a tumor suppressor in T-cells. In human, multiple studies have identified genetic inactivation of Ikaros (deletion or mutation) to be associated with ~5% of T-ALL cases. Additional studies provide evidence that the functional inactivation of Ikaros due to defects in signal pathways that normally regulate Ikaros activity is likely to be a critical factor in the development of Tcell malignancies. These studies provide a rationale for new chemotherapeutic strategies in the treatment of T-cell leukemia. In this chapter, we summarize the newest advances that

The *Ikaros* gene, discovered independently by K. Georgopoulos and S. Smale, encodes multiple Ikaros protein isoforms *via* alternate splicing (Lo et al. 1991; Georgopoulos et al. 1992; Hahm et al. 1994). The structure of Ikaros protein reveals several known structural

The N-terminal region of the Ikaros protein contains four zinc finger motifs (Fig. 1). Three of these exhibit a typical C2H2 structure with two cysteines and two histidines covalently bound to a zinc atom, while the fourth zinc finger has a CCHC structure. The four N terminal zinc fingers in the Ikaros protein function in DNA binding. Point mutational analysis revealed that zinc fingers #2 and #3 are essential for the DNA-binding function of Ikaros, as well as its localization to pericentromeric heterochromatin (see 2.2.1). Based on DNA-se footprint analysis, it has been suggested that the first zinc finger contributes to DNA binding specificity. The role of the fourth zinc finger in DNA-binding remains unknown, although it has been noted that Ikaros isoforms that lack the fourth zinc finger exhibit a unique expression pattern during hematopoiesis (Payne et al. 2003). Recently, a point mutation in a single allele of the fourth zinc finger has been associated with primary

motifs corresponding to distinct functional domains as described below.

immunodeficiency and pancytopenia in humans (Goldman, et al. In press*.).*